

High-Dose Chemotherapy with Hematopoietic Stem-Cell

New England Journal of Medicine

348, 1875-1883

DOI: [10.1056/nejmoa022340](https://doi.org/10.1056/nejmoa022340)

Citation Report

#	ARTICLE	IF	CITATIONS
1	High-dose therapy in multiple myeloma. <i>Annals of Oncology</i> , 2002, 13, 49-54.	0.6	8
2	Anti-idiotypic vaccines. <i>British Journal of Haematology</i> , 2003, 123, 770-781.	1.2	27
3	The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. <i>British Journal of Haematology</i> , 2003, 123, 886-895.	1.2	21
4	Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2003, 349, 2495-2502.	13.9	938
6	Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives. <i>Journal of Clinical Oncology</i> , 2003, 21, 4444-4454.	0.8	113
7	Bortezomib Treatment for Multiple Myeloma. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1825-1830.	0.9	18
8	Treatment of multiple myeloma. <i>BMJ: British Medical Journal</i> , 2003, 327, 575-576.	2.4	6
9	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-398.	2.0	374
10	Multiple Myeloma, 2004 "One or Two Transplants?". <i>New England Journal of Medicine</i> , 2003, 349, 2551-2553.	13.9	16
11	Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion. <i>Anti-Cancer Drugs</i> , 2003, 14, 793-799.	0.7	8
12	Advances in Biology and Therapy of Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 248-278.	0.9	61
13	Transplantation for multiple myeloma: who, when, how often?. <i>Blood</i> , 2003, 102, 3469-3477.	0.6	76
14	"Full length, midi, or mini": a fashion statement for transplants in myeloma. <i>Blood</i> , 2003, 102, 3081-3082.	0.6	6
15	Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. <i>Blood</i> , 2003, 102, 2345-2350.	0.6	90
16	Patient-Reported Outcomes in Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 379-383.	2.3	4
17	Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. <i>Annals of Oncology</i> , 2004, 15, 134-138.	0.6	111
18	Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 1857-1863.	0.8	117
19	Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant. <i>Clinical Cancer Research</i> , 2004, 10, 8170-8176.	3.2	63

#	ARTICLE	IF	CITATIONS
20	Multiple Myeloma. Hematology American Society of Hematology Education Program, 2004, 2004, 237-256.	0.9	76
21	Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma. Clinical Cancer Research, 2004, 10, 3954-3964.	3.2	316
22	Benefit and Timing of Second Transplantations in Multiple Myeloma: Clinical Findings and Methodological Limitations in a European Group for Blood and Marrow Transplantation Registry Study. Journal of Clinical Oncology, 2004, 22, 1674-1681.	0.8	47
23	Strategies to improve the outcome of stem cell transplantation in multiple myeloma. The Hematology Journal, 2004, 5, 9-23.	2.0	14
24	Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. The Hematology Journal, 2004, 5, 318-324.	2.0	126
25	Evolving trends in hematopoietic cell transplantation for solid tumors: tempering enthusiasm with clinical reality. Annals of Oncology, 2004, 15, 543-544.	0.6	2
26	Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. British Journal of Haematology, 2004, 124, 769-776.	1.2	45
27	Treatment advances in multiple myeloma. British Journal of Haematology, 2004, 125, 24-30.	1.2	17
28	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	1.2	74
29	Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. British Journal of Haematology, 2004, 125, 756-765.	1.2	14
30	Improved haematopoietic recovery following transplantation with ex vivo -expanded mobilized blood cells*. British Journal of Haematology, 2004, 126, 536-545.	1.2	39
31	Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. British Journal of Haematology, 2004, 126, 665-674.	1.2	69
32	A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. British Journal of Haematology, 2004, 126, 792-798.	1.2	18
33	A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. British Journal of Haematology, 2004, 127, 299-304.	1.2	117
34	High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplantation, 2004, 33, 61-64.	1.3	50
35	Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplantation, 2004, 33, 955-962.	1.3	67
36	Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells. Bone Marrow Transplantation, 2004, 33, 1209-1214.	1.3	8
37	Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation, 2004, 34, 77-84.	1.3	66

#	ARTICLE	IF	CITATIONS
38	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplantation, 2004, 34, 161-167.	1.3	82
39	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplantation, 2004, 34, 235-239.	1.3	62
40	Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplantation, 2004, 34, 229-234.	1.3	32
41	Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 419-423.	1.3	8
42	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplantation, 2004, 34, 485-490.	1.3	52
43	Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplantation, 2004, 34, 1025-1031.	1.3	102
44	Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplantation, 2004, 34, 1057-1065.	1.3	69
45	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). Leukemia, 2004, 18, 133-138.	3.3	30
46	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 2004, 18, 624-627.	3.3	88
47	Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Leukemia, 2004, 18, 893-893.	3.3	9
48	Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia, 2004, 18, 1420-1426.	3.3	61
49	High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma. European Journal of Haematology, 2004, 73, 169-173.	1.1	3
50	Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. European Journal of Haematology, 2004, 73, 263-268.	1.1	12
51	Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation. European Journal of Haematology, 2004, 72, 26-31.	1.1	8
52	Multiple myeloma: The role of transplant and novel treatment strategies. Seminars in Oncology, 2004, 31, 99-105.	0.8	11
53	Focus on multiple myeloma. Cancer Cell, 2004, 6, 439-444.	7.7	147
54	Unrelated Cord Blood Transplantation with a Reduced-Intensity Conditioning Regimen following Autologous Transplantation for Multiple Myeloma. International Journal of Hematology, 2004, 80, 377-380.	0.7	8
55	Tumors of the Osseous Spine. Journal of Neuro-Oncology, 2004, 69, 273-290.	1.4	96

#	ARTICLE	IF	CITATIONS
58	The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. <i>Hematological Oncology</i> , 2004, 22, 159-168.	0.8	27
59	Stem cell mobilization in multiple myeloma patients: Do we need an age-adjusted regimen for the elderly?. <i>Journal of Clinical Apheresis</i> , 2004, 19, 202-207.	0.7	26
60	Chromosome 13 Deletion/Hypodiploidy and Prognosis in Multiple Myeloma Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 1083-1091.	0.6	11
61	Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 1725-1729.	0.6	7
62	Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. <i>Blood</i> , 2004, 104, 3400-3407.	0.6	204
63	Case 38-2004. <i>New England Journal of Medicine</i> , 2004, 351, 2637-2645.	13.9	10
64	Clinical Course of Patients With Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2004, 79, 867-874.	1.4	319
65	Multiple Myeloma. <i>New England Journal of Medicine</i> , 2004, 351, 1860-1873.	13.9	1,291
66	A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma. <i>European Journal of Cancer</i> , 2004, 40, 1159-1169.	1.3	48
67	Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 395-404.	2.0	48
68	Evolving transplant options for multiple myeloma: Autologous and nonmyeloablative allogeneic. <i>Transplantation Proceedings</i> , 2004, 36, 2501-2503.	0.3	11
69	Recent advances in the management of multiple myeloma. <i>Seminars in Hematology</i> , 2004, 41, 21-26.	1.8	9
70	Multiple myeloma. <i>Lancet, The</i> , 2004, 363, 875-887.	6.3	209
71	New therapeutic targets in multiple myeloma. <i>Lancet, The</i> , 2004, 364, 1648-1649.	6.3	8
72	The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 371-378.	2.3	6
73	Ligands of peroxisome proliferator-activated receptor $\hat{1}^3$ induce apoptosis in multiple myeloma. <i>Anti-Cancer Drugs</i> , 2004, 15, 955-960.	0.7	36
74	A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study. <i>European Journal of Cancer</i> , 2004, 40, 1159-1169.	1.3	41
75	Dendritic Cells in Clinical Trials for Multiple Myeloma. , 2005, 109, 127-136.		9

#	ARTICLE	IF	CITATIONS
76	Thalidomide Effects in the Post-transplantation Setting in Patients with Multiple Myeloma. <i>Hematology</i> , 2004, 9, 35-39.	0.7	7
77	Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma. <i>Hematology</i> , 2004, 9, 17-33.	0.7	13
78	Hematopoietic cell transplantation in multiple myeloma. <i>Current Opinion in Organ Transplantation</i> , 2004, 9, 39-42.	0.8	0
79	Treatment of multiple myeloma. <i>Blood</i> , 2004, 103, 20-32.	0.6	408
80	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. <i>Blood</i> , 2004, 104, 1159-1165.	0.6	134
81	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004, 104, 3052-3057.	0.6	305
82	Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients. <i>Blood</i> , 2004, 104, 1989-1994.	0.6	12
83	The role of PBSCT in treatment of AL amyloidosis is far from settled. <i>Blood</i> , 2004, 104, 2991-2994.	0.6	9
84	Too old for transplantation: think again. <i>Blood</i> , 2004, 104, 3000-3001.	0.6	2
85	Stem Cell Transplantation for Multiple Myeloma. <i>Cancer Control</i> , 2004, 11, 119-129.	0.7	11
86	Advances in the Management of Myeloma. <i>Scottish Medical Journal</i> , 2005, 50, 47-50.	0.7	1
87	Targeted Therapy in Multiple Myeloma. <i>Cancer Control</i> , 2005, 12, 91-104.	0.7	27
88	Stem cell transplantation in multiple myeloma (0, 1, or 2). <i>Current Opinion in Oncology</i> , 2005, 17, 93-98.	1.1	26
89	Progress in hematopoietic stem cell transplantation in multiple myeloma. <i>Current Opinion in Hematology</i> , 2005, 12, 463-470.	1.2	15
90	High dose Chemotherapy and Stem Cell Support in a Patient of Light- and Heavy-chain Deposition Disease with Abnormal Marrow Cell Surface Antigens and No Monoclonal protein. <i>Internal Medicine</i> , 2005, 44, 970-974.	0.3	6
91	Stem cell transplantation in multiple myeloma. <i>Hematology</i> , 2005, 10, 26-28.	0.7	1
92	A Meta-Analysis on Data From 575 Patients With Multiple Myeloma Randomly Assigned to Either High-Dose Therapy or Conventional Therapy. <i>Medicine (United States)</i> , 2005, 84, 250-259.	0.4	25
93	p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. <i>Blood</i> , 2005, 105, 358-360.	0.6	195

#	ARTICLE	IF	CITATIONS
94	Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. <i>Blood</i> , 2005, 105, 350-357.	0.6	29
95	Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. <i>Blood</i> , 2005, 106, 35-39.	0.6	333
96	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. <i>Blood</i> , 2005, 106, 706-712.	0.6	54
97	High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. <i>Blood</i> , 2005, 106, 3755-3759.	0.6	298
98	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. <i>Blood</i> , 2005, 106, 4050-4053.	0.6	604
99	To transplant or not to transplant?. <i>Blood</i> , 2005, 106, 3687-3688.	0.6	3
100	NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. <i>Blood</i> , 2005, 105, 3939-3944.	0.6	173
101	Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. <i>Blood</i> , 2005, 106, 3538-3545.	0.6	39
102	Facteurs pronostiques du myélome utilisables en pratique courante: suivi sur dix ans de 148 malades âgés de plus de 55 ans. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2005, 72, 1299-1305.	0.0	5
103	Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Multiple Myeloma: Results from the Japan Myeloma Study Group. <i>International Journal of Hematology</i> , 2005, 81, 342-348.	0.7	14
104	Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>International Journal of Hematology</i> , 2005, 82, 243-247.	0.7	13
105	Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. <i>Kidney International</i> , 2005, 68, 1464-1471.	2.6	11
106	Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey. <i>British Journal of Haematology</i> , 2005, 128, 510-512.	1.2	20
107	Haplotypes in the tumour necrosis factor region and myeloma. <i>British Journal of Haematology</i> , 2005, 129, 358-365.	1.2	42
108	Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. <i>British Journal of Haematology</i> , 2005, 129, 607-614.	1.2	45
109	PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 755-762.	1.2	313
110	Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 776-783.	1.2	378
111	Uptake of high-dose therapy and peripheral blood stem cell transplantation in myeloma patients < 65 years - the role of the myeloma multi-disciplinary team. <i>British Journal of Haematology</i> , 2005, 130, 318-319.	1.2	2

#	ARTICLE	IF	CITATIONS
112	High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. <i>British Journal of Haematology</i> , 2005, 130, 588-594.	1.2	47
113	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257014.	1.2	73
114	Evolving treatment strategies for myeloma. <i>British Journal of Cancer</i> , 2005, 92, 217-221.	2.9	18
115	Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 35, 33-36.	1.3	71
116	Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. <i>Bone Marrow Transplantation</i> , 2005, 35, 159-164.	1.3	41
117	Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. <i>Bone Marrow Transplantation</i> , 2005, 35, 441-447.	1.3	20
118	The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. <i>Bone Marrow Transplantation</i> , 2005, 35, 609-617.	1.3	59
119	Outcome of unrelated transplants in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 35, 675-681.	1.3	26
120	Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 35, 979-984.	1.3	4
121	Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 35, 971-977.	1.3	64
122	Melphalan 200mg/m ² with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. <i>Bone Marrow Transplantation</i> , 2005, 35, 985-990.	1.3	48
123	Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 35, 1133-1140.	1.3	12
124	An elective single autograft with high-dose melphalan: single-center study of 451 patients. <i>Bone Marrow Transplantation</i> , 2005, 36, 19-24.	1.3	22
125	First-line thalidomide+dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 36, 193-198.	1.3	33
126	Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 36, 315-323.	1.3	53
127	Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 793-796.	1.3	60
128	Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 36, 963-969.	1.3	53
129	Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 36, 951-954.	1.3	9

#	ARTICLE	IF	CITATIONS
130	A phase I study of ¹⁵³ Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. <i>Leukemia</i> , 2005, 19, 118-125.	3.3	46
131	Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. <i>Leukemia</i> , 2005, 19, 910-912.	3.3	19
132	Factors useful for predicting survival of myeloma patients in everyday practice. A 10-year study of 148 patients older than 55 years. <i>Joint Bone Spine</i> , 2005, 72, 544-549.	0.8	3
133	Health related quality of life in patients with multiple myeloma undergoing a double transplantation. <i>European Journal of Haematology</i> , 2005, 74, 136-143.	1.1	45
134	Autografting followed by a reduced-intensity conditioning unrelated donor cord blood transplantation for a patient with refractory multiple myeloma: successful engraftment with minimal toxicity. <i>European Journal of Haematology</i> , 2005, 74, 175-179.	1.1	8
135	Autologous stem cell transplantation in patients with high-risk plasmacytoma. <i>European Journal of Haematology</i> , 2005, 74, 402-406.	1.1	15
136	Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. <i>European Journal of Haematology</i> , 2005, 75, 27-33.	1.1	114
137	Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. <i>European Journal of Haematology</i> , 2005, 75, 376-383.	1.1	61
138	Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. <i>European Journal of Haematology</i> , 2005, 75, 391-395.	1.1	36
139	A novel NF- κ B inhibitor DHMEQ selectively targets constitutive NF- κ B activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. <i>International Journal of Cancer</i> , 2005, 114, 32-38.	2.3	67
140	Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. <i>Cancer</i> , 2005, 104, 1428-1433.	2.0	77
141	Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 214-218.	1.2	47
142	Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003. <i>Irish Journal of Medical Science</i> , 2005, 174, 26-32.	0.8	2
143	Current status of stem cell transplantation for multiple myeloma. <i>Current Treatment Options in Oncology</i> , 2005, 6, 229-240.	1.3	1
144	Treatment of myeloma in patients not eligible for transplantation. <i>Current Treatment Options in Oncology</i> , 2005, 6, 241-253.	1.3	9
145	Religious Struggle and Religious Comfort in Response to Illness: Health Outcomes among Stem Cell Transplant Patients. <i>Journal of Behavioral Medicine</i> , 2005, 28, 359-367.	1.1	130
146	Novel therapy in multiple myeloma. <i>Investigational New Drugs</i> , 2005, 23, 411-415.	1.2	7
147	Advances in biology and treatment of multiple myeloma. <i>Annals of Oncology</i> , 2005, 16, ii106-ii112.	0.6	17

#	ARTICLE	IF	CITATIONS
148	Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patients with multiple myeloma. <i>Annals of Oncology</i> , 2005, 16, 219-221.	0.6	7
149	Long-term survival after surgical intervention for bone disease in multiple myeloma. <i>Annals of Oncology</i> , 2005, 16, 222-227.	0.6	12
150	AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy. <i>Oncologist</i> , 2005, 10, 412-426.	1.9	156
151	Protein Transduction of Dendritic Cells for NY-ESO-1-Based Immunotherapy of Myeloma. <i>Cancer Research</i> , 2005, 65, 10041-10049.	0.4	61
152	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , 2005, 1, 161-167.	1.1	33
153	Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Annals of Oncology</i> , 2005, 16, 611-617.	0.6	13
154	High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe. <i>Journal of Clinical Oncology</i> , 2005, 23, 9227-9233.	0.8	356
155	Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2005, 46, 813-821.	0.6	9
157	Multiple myeloma: an update of developments in targeted therapy. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 379-389.	1.1	4
158	Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. <i>Current Medical Research and Opinion</i> , 2005, 21, 403-411.	0.9	44
159	The Significance of Minimal Residual Disease in Stem Cell Grafts and the Role of Purging: Is It Better to Purge in vivo or in vitro?. <i>Acta Haematologica</i> , 2005, 114, 206-213.	0.7	8
160	Future Directions in Multiple Myeloma Treatment. <i>Acta Haematologica</i> , 2005, 114, 8-13.	0.7	5
161	Role of stem cell transplantation in myeloma. <i>Hematology</i> , 2005, 10, 127-128.	0.7	2
162	Role of allogeneic stem cell transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 455-464.	1.1	3
163	Cure of myeloma: hype or reality?. <i>Bone Marrow Transplantation</i> , 2005, 35, 215-224.	1.3	30
164	Treatment Paradigms for the Newly Diagnosed Patient With Multiple Myeloma. <i>Seminars in Hematology</i> , 2005, 42, S16-S21.	1.8	4
165	Current treatment options for myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1127-1142.	0.9	11
166	Multiple Myeloma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1371-1382.	1.4	210

#	ARTICLE	IF	CITATIONS
167	Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clinic Proceedings, 2005, 80, 1578-1582.	1.4	31
168	The adverse prognostic impact of advanced age in multiple myeloma. Leukemia and Lymphoma, 2005, 46, 951-966.	0.6	31
169	Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma. Leukemia and Lymphoma, 2005, 46, 1217-1222.	0.6	2
170	Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 2005, 23, 9219-9226.	0.8	402
171	Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resistance Updates, 2005, 8, 205-218.	6.5	41
173	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 2005, 352, 2487-2498.	13.9	2,356
174	Evolving Role of Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2005, 6, 89-95.	1.4	8
175	Induction Therapy Before Transplantation in Multiple Myeloma: New Strategies to Achieve Complete Response. Clinical Lymphoma and Myeloma, 2005, 6, 96-101.	1.4	1
176	New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals. Clinical Lymphoma and Myeloma, 2005, 6, 181-190.	1.4	30
177	Risk Stratification of Patients with Newly Diagnosed Multiple Myeloma: Optimizing Treatment Based on Pretreatment Characteristics. Clinical Lymphoma and Myeloma, 2005, 6, 200-207.	1.4	6
178	Stem-cell transplantation in multiple myeloma. Best Practice and Research in Clinical Haematology, 2005, 18, 603-618.	0.7	21
179	Conventional therapy and approach to management. Best Practice and Research in Clinical Haematology, 2005, 18, 585-601.	0.7	6
180	Emerging Therapies for Multiple Myeloma. American Journal of Cancer, 2006, 5, 141-153.	0.4	2
181	Treatment of multiple myeloma: An emphasis on new developments. Annals of Medicine, 2006, 38, 111-115.	1.5	15
183	Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy, 2006, 8, 141-148.	0.3	16
184	The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide + vincristine + doxorubicin + methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leukemia and Lymphoma, 2006, 47, 2335-2338.	0.6	43
185	Investigational treatments for multiple myeloma. Expert Opinion on Investigational Drugs, 2006, 15, 1565-1582.	1.9	7
186	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Review of Anticancer Therapy, 2006, 6, 1769-1785.	1.1	22

#	ARTICLE	IF	CITATIONS
187	New horizons in multiple myeloma therapy. Expert Review of Anticancer Therapy, 2006, 6, 1483-1501.	1.1	1
188	Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1360-1364.	0.6	7
189	Hsp90 Inhibitors in the Clinic. , 2006, , 331-358.		88
190	NY-ESO-1 immunotherapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 2037-2048.	0.6	29
192	Progress in the treatment of multiple myeloma. Lancet, The, 2006, 367, 791-792.	6.3	7
193	Clotting in the air. Lancet, The, 2006, 367, 792-794.	6.3	7
194	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, The, 2006, 367, 825-831.	6.3	775
195	Treatment of a Jehovah's Witness using a transfusion-free autologous stem cell transplant protocol. Community Oncology, 2006, 3, 776-780.	0.2	9
196	Correlation of residual leukocyte subsets with neutropenic fever during severe leukopenia after high-dose chemotherapy and autologous stem cell transplantation. Cytotherapy, 2006, 8, 473-479.	0.3	3
197	Novel Treatment Approaches for Patients with Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 281-288.	1.4	5
198	Immunomodulatory Analogues of Thalidomide in the Treatment of Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 301-305.	1.4	13
199	Cyclophosphamide Mobilization Does Not Improve Outcome in Patients Receiving Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 384-388.	1.4	79
200	Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 469-474.	1.4	16
201	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 475-477.	1.4	22
202	Emerging Role of Novel Combinations for Induction Therapy in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 33-41.	1.4	7
203	Supportive Care in Multiple Myeloma. Clinical Lymphoma and Myeloma, 2006, 7, 42-50.	1.4	4
204	Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy. Annual Review of Medicine, 2006, 57, 33-47.	5.0	317
205	Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2006, 24, 937-944.	0.8	205

#	ARTICLE	IF	CITATIONS
206	Biology and Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 81-86.	2.0	10
207	Using Genomics to Identify High-Risk Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 77-80.	2.0	20
208	Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience. <i>European Journal of Cancer</i> , 2006, 42, 396-402.	1.3	10
209	Allogeneic haematopoietic cell transplantation for multiple myeloma: Reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. <i>European Journal of Cancer</i> , 2006, 42, 1601-1611.	1.3	16
210	State of the art therapy in multiple myeloma and future perspectives. <i>European Journal of Cancer</i> , 2006, 42, 1591-1600.	1.3	30
211	Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. <i>European Journal of Cancer</i> , 2006, 42, 1671-1683.	1.3	60
212	Plasma cell dyscrasias and leukemias. <i>Update on Cancer Therapeutics</i> , 2006, 1, 539-567.	0.9	0
213	Pre-transplant Disease Status is Important for an Improved Outcome of the Second Stem Cell Transplantation in the Myeloma Patients Receiving the First Autologous Stem Cell Transplantation. <i>The Korean Journal of Hematology</i> , 2006, 41, 36.	0.7	1
214	Bortezomib: the evidence of its clinical impact in multiple myeloma. <i>Core Evidence</i> , 2006, Volume 1-Issues 3 & 4, 0-0.	4.7	1
216	Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. <i>Blood</i> , 2006, 107, 2633-2638.	0.6	129
217	Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. <i>Blood</i> , 2006, 108, 2165-2172.	0.6	373
218	Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , 2006, 108, 3289-3294.	0.6	639
219	Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. <i>Blood</i> , 2006, 107, 463-466.	0.6	62
220	Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. <i>Blood</i> , 2006, 107, 397-403.	0.6	94
221	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. <i>Blood</i> , 2006, 107, 3384-3388.	0.6	64
222	Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. <i>Blood</i> , 2006, 107, 3474-3480.	0.6	344
223	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. <i>Blood</i> , 2006, 107, 4039-4046.	0.6	139
224	Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. <i>Blood</i> , 2006, 108, 2013-2019.	0.6	88

#	ARTICLE	IF	CITATIONS
225	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , 2006, 108, 3458-3464.	0.6	494
227	Current status of new drugs for the treatment of patients with multiple myeloma. <i>Internal Medicine Journal</i> , 2006, 36, 781-789.	0.5	24
228	A single dose of 6 or 12µg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. <i>Transfusion</i> , 2006, 46, 180-185.	0.8	60
229	Guidelines on the diagnosis and management of multiple myeloma 2005. <i>British Journal of Haematology</i> , 2006, 132, 410-451.	1.2	234
230	Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. <i>British Journal of Haematology</i> , 2006, 133, 389-396.	1.2	75
231	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. <i>British Journal of Haematology</i> , 2006, 134, 37-44.	1.2	18
232	The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. <i>British Journal of Haematology</i> , 2006, 134, 385-390.	1.2	55
233	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. <i>British Journal of Haematology</i> , 2006, 134, 417-425.	1.2	84
234	Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience. <i>International Journal of Laboratory Hematology</i> , 2006, 28, 189-197.	0.2	8
235	Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 65-72.	1.3	11
236	Cure of multiple myeloma – more hype, less reality. <i>Bone Marrow Transplantation</i> , 2006, 37, 1-18.	1.3	26
237	Sequential, cycling maintenance therapy for post transplant multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 89-94.	1.3	5
238	Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come. <i>Bone Marrow Transplantation</i> , 2006, 37, 239-247.	1.3	7
239	Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. <i>Bone Marrow Transplantation</i> , 2006, 37, 731-737.	1.3	100
240	High-dose melphalan (200µg/m ²) supported by autologous stem cell transplantation is safe and effective in elderly (>65 years) myeloma patients: comparison with younger patients treated on the same protocol. <i>Bone Marrow Transplantation</i> , 2006, 37, 917-922.	1.3	96
241	Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2006, 37, 1037-1042.	1.3	61
242	Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. <i>Bone Marrow Transplantation</i> , 2006, 38, 7-15.	1.3	107
243	Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 339-343.	1.3	62

#	ARTICLE	IF	CITATIONS
244	MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 555-560.	1.3	28
245	Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?. <i>Bone Marrow Transplantation</i> , 2006, 38, 585-592.	1.3	28
246	Autologous stem cell transplantation beyond 60 years of age. <i>Bone Marrow Transplantation</i> , 2006, 38, 715-720.	1.3	31
247	Results of a phase I/II trial adding carmustine (300â€‰%mg/m ²) to melphalan (200â€‰%mg/m ²) in multiple myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia</i> , 2006, 20, 345-349.	3.3	13
248	International uniform response criteria for multiple myeloma. <i>Leukemia</i> , 2006, 20, 1467-1473.	3.3	2,332
249	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006, 30, 283-285.	0.4	17
250	Current Status of Hematopoietic Cell Transplantation for Adult Patients with Hematologic Diseases and Solid Tumors in Japan. <i>International Journal of Hematology</i> , 2006, 83, 164-178.	0.7	19
251	Recurrence of Autoimmune Disease after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 84, 354-358.	0.7	8
252	Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin and mitoxantrone. <i>Investigational New Drugs</i> , 2006, 24, 529-35.	1.2	68
253	Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. <i>Annals of Hematology</i> , 2006, 85, 191-193.	0.8	12
254	Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma. <i>Annals of Hematology</i> , 2006, 85, 394-399.	0.8	10
255	Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. <i>European Journal of Haematology</i> , 2006, 76, 245-250.	1.1	52
256	Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?. <i>European Journal of Haematology</i> , 2006, 77, 239-244.	1.1	17
257	Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. <i>European Journal of Haematology</i> , 2006, 77, 410-415.	1.1	38
258	Revisiting the role of dose intensity in hematological malignancies. <i>Experimental Hematology</i> , 2006, 34, 811-825.	0.2	4
259	Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. <i>Experimental Hematology</i> , 2006, 34, 1296-1302.	0.2	28
260	First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 399-404.	1.1	51
261	Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. <i>European Journal of Haematology</i> , 2006, 77, 486-492.	1.1	30

#	ARTICLE	IF	CITATIONS
262	Prospective randomised comparison of the COBE Spectra version 6 and Haemonetics MCS+ cell separators for hematopoietic progenitor cells leucapheresis in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2006, 21, 111-115.	0.7	7
263	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. <i>Cancer</i> , 2006, 106, 1084-1089.	2.0	69
264	Complete response in multiple myeloma. <i>Cancer</i> , 2006, 106, 1958-1966.	2.0	60
265	Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. <i>Cancer</i> , 2006, 106, 2171-2180.	2.0	45
266	Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. <i>Hematological Oncology</i> , 2006, 24, 205-211.	0.8	10
267	Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. <i>American Journal of Hematology</i> , 2006, 81, 426-431.	2.0	59
268	High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. <i>American Journal of Hematology</i> , 2006, 81, 973-978.	2.0	7
269	Autologous peripheral stem cell transplant for POEMS syndrome: A case report. <i>Hematology</i> , 2006, 11, 361-363.	0.7	5
270	Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2006, 24, 334-336.	0.8	51
271	Myeloma – new approaches to combined nephrological haematological management. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 582-590.	0.4	31
272	Bortezomib for multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1337-1346.	0.9	12
273	Pharmacotherapy of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 767-781.	0.9	4
274	High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 343-360.	1.1	21
275	Thalidomide in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 195-213.	0.9	16
276	Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. <i>Journal of Clinical Oncology</i> , 2006, 24, 929-936.	0.8	464
277	Multiple Myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1322-1330.	2.2	35
278	Targeting Signaling Pathways in Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 407-413.	0.9	4
279	Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 449-453.	0.9	5

#	ARTICLE	IF	CITATIONS
280	High-Dose Therapy in Patients with Plasma Cell Dyscrasias and Renal Dysfunction. , 2006, 153, 182-194.		13
281	Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leukemia and Lymphoma, 2006, 47, 43-47.	0.6	45
282	Poor Outcome With Front-Line Autologous Transplantation in t(4;14) Multiple Myeloma: Low Complete Remission Rate and Short Duration of Remission. Journal of Clinical Oncology, 2006, 24, e4-e5.	0.8	31
283	Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2006, 354, 1021-1030.	13.9	684
284	Efficacy of Up-Front Treatment with a Double Stem Cell Transplantation in Multiple Myeloma. Japanese Journal of Clinical Oncology, 2006, 36, 432-438.	0.6	8
285	Hematological malignancies: myeloma. Annals of Oncology, 2006, 17, x136-x143.	0.6	8
286	Tissue Stem Cells. , 0, , .		6
287	Multiple Myeloma. Journal of the American Society of Nephrology: JASN, 2006, 17, 2533-2545.	3.0	137
288	Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies. Current Cancer Therapy Reviews, 2006, 2, 169-183.	0.2	0
289	Poorex vivoinduction of T-cell responses to idiotypic or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1340-1347.	0.6	4
290	A Novel HSV-1 Virus, JS1/34.5/47, Purges Contaminating Breast Cancer Cells From Bone Marrow. Clinical Cancer Research, 2006, 12, 6853-6862.	3.2	14
291	Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2006, 24, 431-436.	0.8	802
292	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	0.8	301
293	Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma. Oncologist, 2007, 12, 978-990.	1.9	30
294	Management of paraproteinaemia. Postgraduate Medical Journal, 2007, 83, 217-223.	0.9	36
295	Melphalan and its role in the management of patients with multiple myeloma. Expert Review of Anticancer Therapy, 2007, 7, 945-957.	1.1	43
296	The Role of High-Dose Chemotherapy Supported by Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma: Implications for Nursing. Clinical Journal of Oncology Nursing, 2007, 11, 569-589.	0.3	6
297	A Case of Atypical Light Chain Deposition Disease Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 858-867.	2.2	18

#	ARTICLE	IF	CITATIONS
298	Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. <i>Annals of Oncology</i> , 2007, 18, 623-632.	0.6	38
299	Bone Marrow and Peripheral Blood Stem Cell Transplantation. , 2007, , 787-822.		0
300	Stem Cell Transplantation in Multiple Myeloma. Hematology American Society of Hematology Education Program, 2007, 2007, 311-316.	0.9	10
301	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	13.9	479
302	Recommendations for use of Tumor Markers in Monoclonal Gammopathies. <i>Journal of Medical Biochemistry</i> , 2007, 26, 165-172.	0.7	0
303	Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. <i>Haematologica</i> , 2007, 92, 1399-1406.	1.7	265
304	OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms. <i>Clinical Cancer Research</i> , 2007, 13, 4750-4758.	3.2	53
305	An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon- β 2b in patients with multiple myeloma maintained on a steady dose of interferon- β 2b. <i>Annals of Oncology</i> , 2007, 18, 1388-1394.	0.6	22
306	New Drugs for Myeloma. <i>Oncologist</i> , 2007, 12, 664-689.	1.9	145
307	Cancer Stem Cells. , 2007, , .		2
308	Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics. <i>Journal of Clinical Oncology</i> , 2007, 25, 4452-4458.	0.8	106
309	Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii44-ii46.	0.6	4
310	Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype. <i>Acta Haematologica</i> , 2007, 118, 27-29.	0.7	7
312	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2434-2441.	0.8	329
313	Relationship Between Depth of Response and Outcome in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4933-4937.	0.8	40
314	A Single-Chain Fv Diabody against Human Leukocyte Antigen-A Molecules Specifically Induces Myeloma Cell Death in the Bone Marrow Environment. <i>Cancer Research</i> , 2007, 67, 1184-1192.	0.4	29
315	Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 802-810.	1.9	24
316	Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1774-1784.	1.9	82

#	ARTICLE	IF	CITATIONS
317	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. <i>Blood</i> , 2007, 110, 3561-3563.	0.6	154
318	Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 163-169.	2.3	3
319	Chemotherapy and Survival for Patients With Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 540-548.	0.6	16
320	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007, 82, 323-341.	1.4	143
321	Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. <i>Haematologica</i> , 2007, 92, 1505-1512.	1.7	33
322	Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. <i>Hematology</i> , 2007, 12, 235-239.	0.7	101
323	Beta-2-Microglobulin Level Predicts Outcome Following Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma. <i>Transplantation Proceedings</i> , 2007, 39, 2893-2897.	0.3	15
324	Medical management update: Multiple myeloma. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2007, 103, 599-609.	1.6	36
325	The EORTC QLQ-HDC29: A supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation. <i>European Journal of Cancer</i> , 2007, 43, 87-94.	1.3	29
326	High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 183-196.	2.0	216
327	Cancer Stem Cells: From Bench to Bedside. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 47-52.	2.0	18
328	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 423-432.	2.0	40
329	Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with ¹⁶⁶ Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 543-549.	2.0	29
330	Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 925-931.	2.0	44
331	Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 877-885.	2.0	22
332	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1066-1072.	2.0	40
333	Multiple Myeloma in a 50-Year-Old with an HLA-Identical Sibling. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1247-1248.	2.0	0
334	Haplotypic structure across the $\hat{\imath}^{\circ}\hat{\imath}^{\pm}$ gene (NFKBIA) and association with multiple myeloma. <i>Cancer Letters</i> , 2007, 246, 92-99.	3.2	32

#	ARTICLE	IF	CITATIONS
335	Lenalidomide in Myeloma. <i>Current Treatment Options in Oncology</i> , 2007, 8, 154-163.	1.3	6
336	Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99â€™06): a randomised trial. <i>Lancet, The</i> , 2007, 370, 1209-1218.	6.3	820
337	High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future. <i>Seminars in Hematology</i> , 2007, 44, 227-233.	1.8	28
338	Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials. <i>International Reviews of Immunology</i> , 2007, 26, 197-222.	1.5	10
339	Advances in the treatment of multiple myeloma in patients with chromosome 13 abnormalities. <i>Community Oncology</i> , 2007, 4, 137-140.	0.2	0
340	Prognostic Factors and Staging in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1115-1140.	0.9	40
341	Treatment Strategies in Elderly Patients with Multiple Myeloma. <i>Drugs and Aging</i> , 2007, 24, 829-850.	1.3	4
342	An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 261-269.	1.4	29
343	The treatment of the elderly multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 469-480.	0.6	4
344	CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: A retrospective study. <i>Leukemia and Lymphoma</i> , 2007, 48, 506-512.	0.6	9
345	Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment. <i>Leukemia and Lymphoma</i> , 2007, 48, 1910-1921.	0.6	37
346	Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2345-2351.	0.6	40
347	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1179-1184.	1.4	142
348	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. <i>Mayo Clinic Proceedings</i> , 2007, 82, 323-341.	1.4	155
349	Role of Stem Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1157-1174.	0.9	22
350	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. <i>Blood</i> , 2007, 109, 2767-2772.	0.6	174
352	Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. <i>Journal of Translational Medicine</i> , 2007, 5, 35.	1.8	7
353	Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma. <i>Drugs</i> , 2007, 67, 1869-1881.	4.9	37

#	ARTICLE	IF	CITATIONS
354	Current Treatment Strategies for Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S139-S144.	1.4	8
355	Current Standards for First-Line Therapy of Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S207-S214.	1.4	15
356	Multiple Myeloma: Novel Approaches for Relapsed Disease. <i>Clinical Lymphoma and Myeloma</i> , 2007, 8, S18-S23.	1.4	5
357	Lenalidomide in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 717-735.	0.7	13
358	The Arkansas approach to therapy of patients with multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 761-781.	0.7	31
359	Role of autologous stem-cell transplantation in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 747-759.	0.7	25
360	Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 665-680.	0.7	42
361	Melphalan: old and new uses of a still master drug for multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1467-1487.	1.9	17
362	Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. <i>Haematologica</i> , 2007, 92, 928-935.	1.7	73
363	Strategies to Eliminate Cancer Stem Cells. , 2007, , 219-230.		0
364	Current status and future directions in the treatment of multiple myeloma. <i>Chinese Medical Journal</i> , 2007, 120, 1651-1654.	0.9	1
366	Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. <i>American Journal of Hematology</i> , 2007, 82, 1071-1075.	2.0	15
367	Limited feasibility of double transplant in multiple myeloma. <i>Cancer</i> , 2007, 109, 2273-2278.	2.0	9
368	Time to first disease progression, but not \hat{I}^{22} -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007, 110, 824-829.	2.0	19
369	High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. <i>Leukemia Research</i> , 2007, 31, 1063-1068.	0.4	4
371	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 279-283.	1.3	41
372	Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 389-396.	1.3	37
373	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 605-611.	1.3	57

#	ARTICLE	IF	CITATIONS
374	Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 695-703.	1.3	8
375	High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. <i>Bone Marrow Transplantation</i> , 2007, 40, 1101-1114.	1.3	27
376	Autologous stem cell transplantation in the elderly including pre- and post-treatment options. <i>Bone Marrow Transplantation</i> , 2007, 40, 1115-1121.	1.3	2
377	Molecular remission of multiple myeloma with cytoreductive autografting followed by a dose-reduced allograft. <i>Bone Marrow Transplantation</i> , 2007, 40, 997-999.	1.3	0
378	Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma. <i>Bone Marrow Transplantation</i> , 2007, 40, 1147-1155.	1.3	0
379	The evolving background for high-dose treatment for myeloma. <i>Bone Marrow Transplantation</i> , 2007, 40, 1097-1100.	1.3	5
380	Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. <i>Leukemia</i> , 2007, 21, 164-168.	3.3	113
381	Maintenance therapy in multiple myeloma. <i>Leukemia</i> , 2007, 21, 1150-1157.	3.3	41
382	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. <i>Leukemia</i> , 2007, 21, 2035-2042.	3.3	317
383	Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. <i>Leukemia</i> , 2007, 21, 2020-2024.	3.3	84
384	Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2007, 30, 070222025146002-???	0.2	4
385	Place de l'autogreffe de cellules souches h�matopo�tiques dans le traitement des h�mopathies de l'adulte. <i>Revue Francophone Des Laboratoires</i> , 2007, 2007, 37-44.	0.0	0
386	A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. <i>British Journal of Haematology</i> , 2007, 136, 203-211.	1.2	79
387	Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. <i>British Journal of Haematology</i> , 2007, 136, 393-399.	1.2	63
388	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. <i>British Journal of Haematology</i> , 2007, 138, 176-185.	1.2	304
389	Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. <i>British Journal of Haematology</i> , 2007, 139, 429-433.	1.2	35
390	In vivo and in silico studies on single versus multiple transplants for multiple myeloma. <i>Cancer Science</i> , 2007, 98, 734-739.	1.7	6
391	Serum M-spike and transplant outcome in patients with multiple myeloma. <i>Cancer Science</i> , 2007, 98, 1035-1040.	1.7	15

#	ARTICLE	IF	CITATIONS
392	Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. <i>Cancer Science</i> , 2007, 99, 071029014002001-???.	1.7	51
393	Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. <i>Cancer Science</i> , 2007, 99, 071027181834001-???.	1.7	20
394	Outpatient high-dose melphalan in multiple myeloma patients. <i>Transfusion</i> , 2007, 47, 115-119.	0.8	20
395	Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. <i>Transfusion</i> , 2007, 47, 2207-2216.	0.8	21
396	Multiple Myeloma: Charging Toward a Bright Future. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 301-318.	157.7	82
397	Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. <i>Experimental Hematology</i> , 2007, 35, 1839-1846.	0.2	47
398	Chromosomal abnormalities of young multiple myeloma patients (<45â€ƒyr) are not different from those of other age groups and are independent of stage according to the International Staging System. <i>European Journal of Haematology</i> , 2007, 78, 227-234.	1.1	19
399	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	1.1	25
400	Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>International Journal of Hematology</i> , 2007, 85, 408-414.	0.7	46
402	Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. <i>Annals of Hematology</i> , 2007, 86, 277-282.	0.8	13
403	Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide. <i>Annals of Hematology</i> , 2007, 86, 575-581.	0.8	5
404	Proteasome inhibitor, bortezomib, for myeloma and lymphoma. <i>International Journal of Clinical Oncology</i> , 2007, 12, 318-326.	1.0	42
405	New therapies in multiple myeloma. <i>Clinical and Experimental Medicine</i> , 2007, 7, 83-97.	1.9	37
406	Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 134, 245-253.	1.2	59
407	Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation. <i>Current Treatment Options in Oncology</i> , 2007, 8, 135-143.	1.3	4
408	Role of autologous stem cell transplantation in multiple myeloma. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 121-127.	1.2	0
409	Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. <i>Annals of Hematology</i> , 2008, 87, 49-55.	0.8	25
410	Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. <i>Annals of Hematology</i> , 2008, 87, 623-631.	0.8	38

#	ARTICLE	IF	CITATIONS
411	Paraproteinämien / Multiples Myelom. Wiener Klinische Wochenschrift Education, 2008, 3, 93-105.	0.0	0
412	Role of allogeneic stem cell transplantation in multiple myeloma. Current Hematologic Malignancy Reports, 2008, 3, 99-106.	1.2	3
413	Historical perspective and advances in the treatment of multiple myeloma. Oncology Reviews, 2008, 2, 250-258.	0.8	0
415	High-dose melphalan-based autotransplants for multiple myeloma. Cancer, 2008, 112, 1754-1764.	2.0	15
416	The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. American Journal of Hematology, 2008, 83, 355-358.	2.0	41
417	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. American Journal of Hematology, 2008, 83, 614-617.	2.0	123
418	Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Leukemia Research, 2008, 32, 1085-1090.	0.4	3
419	Frontline treatment of multiple myeloma in elderly patients. Blood Reviews, 2008, 22, 303-309.	2.8	11
420	Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival. Journal of Clinical Oncology, 2008, 26, 5775-5782.	0.8	263
421	Increased fatty acid synthase as a potential therapeutic target in multiple myeloma. Journal of Zhejiang University: Science B, 2008, 9, 441-447.	1.3	43
422	Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 2008, 22, 1343-1353.	3.3	42
423	Current status of autologous hematopoietic stem cell transplantation in myeloma. Bone Marrow Transplantation, 2008, 42, S28-S34.	1.3	10
424	Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours. Bone Marrow Transplantation, 2008, 42, 167-173.	1.3	1
425	Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplantation, 2008, 42, 259-264.	1.3	10
426	Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplantation, 2008, 42, 413-420.	1.3	87
427	Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplantation, 2008, 41, 953-960.	1.3	62
428	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplantation, 2008, 41, 1013-1019.	1.3	20
429	Survival from multiple myeloma in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S113-S115.	2.9	2

#	ARTICLE	IF	CITATIONS
430	Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 749-757.	2.3	46
431	Clinically relevant end points and new drug approvals for myeloma. <i>Leukemia</i> , 2008, 22, 231-239.	3.3	192
432	Position statement on the use of bortezomib in multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 1-10.	0.7	15
433	MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome. <i>Cancer Science</i> , 2008, 99, 720-725.	1.7	42
434	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. <i>British Journal of Haematology</i> , 2008, 141, 205-211.	1.2	20
435	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 46-53.	1.2	94
436	Infusion of haploidentical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2008, 143, 641-653.	1.2	175
437	Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. <i>British Journal of Haematology</i> , 2008, 143, 349-354.	1.2	20
438	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008, 143, 511-519.	1.2	55
439	Delayed complete remission in a patient with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2008, 38, 966-968.	1.7	1
440	Assessment of the role of timing of second transplantation in multiple myeloma by multistate modeling. <i>Experimental Hematology</i> , 2008, 36, 1567-1571.	0.2	6
441	Multiple myeloma – an update on diagnosis and treatment. <i>European Journal of Haematology</i> , 2008, 81, 329-343.	1.1	46
442	Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 315-317.	1.4	12
444	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	13.9	1,787
445	Multiple Myeloma: Primary Bone Tumor with Systemic Manifestations. <i>Neurosurgery Clinics of North America</i> , 2008, 19, 31-40.	0.8	22
446	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 351-352.	2.0	8
447	Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1039-1044.	2.0	53
448	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1045-1056.	2.0	319

#	ARTICLE	IF	CITATIONS
449	Comparison of Twin and Autologous Transplants for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1118-1124.	2.0	28
450	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.	2.0	27
451	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1401-1407.	2.0	39
452	A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. <i>Cancer Treatment Reviews</i> , 2008, 34, 442-452.	3.4	71
453	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. <i>Cytokine</i> , 2008, 41, 244-253.	1.4	41
454	Meeting Highlights. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 77-86.	1.4	0
455	Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. <i>Cytotherapy</i> , 2008, 10, 30-37.	0.3	19
456	Treatment of Myeloma: Cure vs Control. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1142-1145.	1.4	64
457	The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1436-1451.	0.6	4
458	Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy. <i>Leukemia and Lymphoma</i> , 2008, 49, 2272-2283.	0.6	13
459	High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later. <i>Journal of Clinical Oncology</i> , 2008, 26, 2240-2243.	0.8	19
460	MATHEMATICAL MODELS OF CANCER AND THEIR RELEVANT INSIGHTS. <i>Series in Mathematical Biology and Medicine</i> , 2008, , 173-223.	0.1	8
461	Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs. <i>Journal of Clinical Oncology</i> , 2008, 26, 480-492.	0.8	55
462	An update on drug combinations for treatment of myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1-12.	1.9	10
463	Induction Therapy in Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 306-312.	0.9	26
464	Bortezomib in multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 639-654.	1.5	22
465	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008, 111, 2516-2520.	0.6	2,022
466	Treatment of relapsed and refractory myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1470-1485.	0.6	12

#	ARTICLE	IF	CITATIONS
467	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2171-2177.	0.8	322
468	Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii55-ii57.	0.6	12
469	Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, 1160-1165.	0.6	101
470	New treatments in multiple myeloma: beyond optimal treatment. <i>Annals of Oncology</i> , 2008, 19, v68-v70.	0.6	5
471	Autologous transplantation for multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, vii128-vii133.	0.6	10
472	Lenalidomide and its role in the management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 865-874.	1.1	15
473	Modern Treatment Options for Elderly Patients with Multiple Myeloma. <i>Onkologie</i> , 2008, 31, 10-10.	1.1	0
475	Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. <i>Blood</i> , 2008, 111, 1805-1810.	0.6	119
476	153Sm: its use in multiple myeloma and report of a clinical experience. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1379-1387.	1.9	15
477	The effect of azacitidine on interleukin-6 signaling and nuclear factor- κ B activation and its in vitro and in vivo activity against multiple myeloma. <i>Haematologica</i> , 2008, 93, 860-869.	1.7	43
478	Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. <i>Blood</i> , 2008, 111, 94-100.	0.6	73
479	Multiple myeloma. <i>Blood</i> , 2008, 111, 2962-2972.	0.6	759
480	One or two autografts for myeloma?. <i>Blood</i> , 2008, 111, 3899-3900.	0.6	4
481	A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , 2008, 112, 3591-3593.	0.6	247
482	AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA. , 0, , 86-100.		0
483	TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA. , 0, , 26-36.		0
484	Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. <i>Haematologica</i> , 2008, 93, 1343-1350.	1.7	18
485	Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience. <i>Journal of Korean Medical Science</i> , 2008, 23, 819.	1.1	16

#	ARTICLE	IF	CITATIONS
486	Monoclonal gammopathies. , 2008, , 1167-1180.		1
487	Full PDF of Hematology Reviews 2009, volume 1, issue 1.. Hematology Reports, 2009, 1, 1.	0.3	0
488	Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma. , 0, , 139-156.		0
489	Histone deacetylase inhibitors in multiple myeloma. Hematology Reports, 2009, 1, 9.	0.3	1
490	Does stem cell transplantation have a role in the management of multiple myeloma, 2009?. Expert Opinion on Pharmacotherapy, 2009, 10, 1-4.	0.9	5
491	Rapid Immune Recovery and Graft-versus-Host Disease“like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells. Clinical Cancer Research, 2009, 15, 4499-4507.	3.2	91
492	Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all- <i>trans</i> retinoic acid. Leukemia and Lymphoma, 2009, 50, 966-973.	0.6	5
493	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. Acta Haematologica, 2009, 122, 200-210.	0.7	28
494	Flow Cytometric Immunophenotyping and Minimal Residual Disease Analysis in Multiple Myeloma. American Journal of Clinical Pathology, 2009, 132, 728-732.	0.4	55
495	Initial therapy in multiple myeloma: investigating the new treatment paradigm. Journal of Oncology Pharmacy Practice, 2009, 15, 131-141.	0.5	2
496	Quality of Life after Autologous Peripheral Blood Stem Cell Transplantation and High-Dose Chemotherapy in High-Risk Breast Cancer Patients. Breast Care, 2009, 4, 379-386.	0.8	2
497	How to treat a newly diagnosed young patient with multiple myeloma. Hematology American Society of Hematology Education Program, 2009, 2009, 555-565.	0.9	16
498	Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs, 2009, 1, 548-551.	2.6	58
499	Monitoring of plasma cell proliferative and apoptotic indices in the course of multiple myeloma. Leukemia and Lymphoma, 2009, 50, 1983-1991.	0.6	2
500	Emerging therapies for multiple myeloma. Expert Opinion on Emerging Drugs, 2009, 14, 99-127.	1.0	48
502	Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 2009, 8, 2616-2624.	1.9	161
503	Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma. Clinical Cancer Research, 2009, 15, 4356-4364.	3.2	69
504	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 714-722.	3.2	27

#	ARTICLE	IF	CITATIONS
505	Retrospective Comparison of Bortezomib-containing Regimens with Vincristine-Doxorubicin-Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 449-455.	0.6	9
506	Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv97-iv99.	0.6	17
507	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	1.1	21
508	Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. <i>European Journal of Haematology</i> , 2009, 82, 433-439.	1.1	21
509	All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. <i>European Journal of Haematology</i> , 2009, 83, 191-202.	1.1	11
510	Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. <i>European Journal of Haematology</i> , 2009, 83, 279-289.	1.1	46
511	Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. <i>Biochemical Pharmacology</i> , 2009, 78, 45-53.	2.0	44
512	Spatiotemporal Control over Molecular Delivery and Cellular Encapsulation from Electropolymerized Micro- and Nanopatterned Surfaces. <i>Advanced Functional Materials</i> , 2009, 19, 2888-2895.	7.8	9
513	Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2009, 84, 809-814.	2.0	23
514	Peripheral blood stem cell collection in multiple myeloma: A retrospective analysis of 6 years leukapheresis activity in 109 patients treated at the Istituto Nazionale dei Tumori of Milan. <i>Journal of Clinical Apheresis</i> , 2009, 24, 134-140.	0.7	4
515	Preparation and biodistribution of [¹²⁵ I]Melphalan: a potential radioligand for diagnostic and therapeutic applications. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 1-5.	0.5	6
516	Multiple Myeloma. <i>Current Problems in Cancer</i> , 2009, 33, 7-64.	1.0	64
517	Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. <i>International Journal of Hematology</i> , 2009, 89, 45-57.	0.7	27
518	Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NF- κ B p65. <i>International Journal of Hematology</i> , 2009, 90, 513-521.	0.7	46
519	Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma. <i>International Journal of Hematology</i> , 2009, 90, 635-642.	0.7	11
520	Cancer stem cells' clinical relevance. <i>Journal of Molecular Medicine</i> , 2009, 87, 1105-1110.	1.7	21
521	Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 484-498.	3.3	19
522	Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells. <i>Cancer Science</i> , 2009, 100, 1137-1143.	1.7	1

#	ARTICLE	IF	CITATIONS
523	High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. <i>British Journal of Haematology</i> , 2009, 144, 169-175.	1.2	101
524	The peptideâ€šemicarbazone Sâ€š2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells. <i>British Journal of Haematology</i> , 2009, 144, 875-886.	1.2	17
525	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2009, 145, 681-708.	1.2	31
526	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 147, 531-534.	1.2	27
527	Role of autologous and allogeneic stem cell transplantation in myeloma. <i>Leukemia</i> , 2009, 23, 442-448.	3.3	55
528	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). <i>Leukemia</i> , 2009, 23, 1152-1157.	3.3	176
529	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. <i>Leukemia</i> , 2009, 23, 1337-1341.	3.3	347
530	Is the international staging system superior to the Durieâ€šSalmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. <i>Leukemia</i> , 2009, 23, 1528-1534.	3.3	81
531	EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. <i>Bone Marrow Transplantation</i> , 2009, 43, 197-206.	1.3	17
532	Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 223-228.	1.3	31
533	Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2009, 43, 417-422.	1.3	91
534	High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. <i>Bone Marrow Transplantation</i> , 2009, 43, 481-489.	1.3	19
535	Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. <i>Bone Marrow Transplantation</i> , 2009, 43, 793-800.	1.3	26
536	In pursuit of the allo-immune response in multiple myeloma: where do we go from here?. <i>Bone Marrow Transplantation</i> , 2009, 43, 91-99.	1.3	10
537	Outcomes after auto-SCT in African Americans with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2009, 43, 845-851.	1.3	4
538	Improving stem cell mobilization strategies: future directions. <i>Bone Marrow Transplantation</i> , 2009, 43, 181-195.	1.3	194
539	Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. <i>Bone Marrow Transplantation</i> , 2009, 43, 927-934.	1.3	14
540	BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2009, 44, 157-161.	1.3	17

#	ARTICLE	IF	CITATIONS
541	Safety and efficacy results from an international Expanded Access Programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients. <i>Internal Medicine Journal</i> , 2009, 39, 290-295.	0.5	3
542	Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly. <i>Geriatrics and Gerontology International</i> , 2009, 9, 115-123.	0.7	4
543	High complete remission rate and durable remissions achieved with rational use of autologous stem cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma. <i>Clinical Transplantation</i> , 2009, 23, 839-847.	0.8	2
544	United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 119-131.	0.7	1
545	Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 1475-1480.	0.4	75
546	Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. <i>Leukemia Research</i> , 2009, 33, e145-e149.	0.4	11
547	Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. <i>Leukemia Research</i> , 2009, 33, 1615-1618.	0.4	14
548	Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 5720-5726.	0.8	155
549	The impact of extramedullary disease at presentation on the outcome of myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 230-235.	0.6	97
550	Changes in Quality-of-Life and Psychosocial Adjustment among Multiple Myeloma Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 12-20.	2.0	101
551	Is There a Role for Autotransplants in AML in First Remission?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 17-20.	2.0	13
552	Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 718-723.	2.0	150
553	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 812-816.	2.0	68
554	Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 686-693.	2.0	24
555	Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era. <i>Annals of Pharmacotherapy</i> , 2009, 43, 329-338.	0.9	11
556	Thrombopoietic Cytokine and P-Selectin Levels in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Decrease in Posttransplantation P-Selectin Levels Might Predict the Degree of Maximum Response. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 229-233.	1.4	5
557	Treatment of Multiple Myeloma: A Comprehensive Review. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 278-288.	1.4	135
558	Long-Term Outcomes of Autologous Transplantation in Multiple Myeloma: Significant Survival Benefit of Novel Drugs in Post-Transplantation Relapse. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 436-442.	1.4	11

#	ARTICLE	IF	CITATIONS
559	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. <i>Advances in Hematology</i> , 2009, 2009, 1-5.	0.6	14
560	Primary Malignant Tumors of the Spine. <i>Orthopedic Clinics of North America</i> , 2009, 40, 21-36.	0.5	139
561	Etoposide 1.0 g/m ² or 1.5 g/m ² combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity. <i>Cytotherapy</i> , 2009, 11, 362-371.	0.3	5
562	Curcumin circumvents chemoresistance <i>in vitro</i> and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 959-970.	1.9	141
563	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. <i>Journal of Clinical Oncology</i> , 2009, 27, 1788-1793.	0.8	315
564	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 781-787.	0.6	6
565	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. <i>Blood</i> , 2009, 114, 1729-1735.	0.6	203
566	Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1442-1447.	0.6	41
567	Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1239-1248.	0.6	12
568	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 216-222.	0.6	24
569	New generation pharmacotherapy in elderly multiple myeloma patients. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 81-98.	0.9	3
570	The Activity of Spanish and Italian Myeloma Groups. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S36-S39.	1.4	0
571	Phase III Trials for Multiple Myeloma in Northern Europe. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S39.	1.4	0
572	Statistical Issues in the Design and Analysis of Clinical Studies in Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S39.	1.4	0
573	Timing of Stem Cell Transplantation in the Era of Novel Agents. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S49-S51.	1.4	0
574	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S51-S52.	1.4	1
575	The role of complete response in multiple myeloma. <i>Blood</i> , 2009, 114, 3139-3146.	0.6	206
576	Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 158-165.	1.8	14

#	ARTICLE	IF	CITATIONS
577	Front-Line Treatment in Younger Patients With Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 118-126.	1.8	18
578	The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents. <i>Seminars in Hematology</i> , 2009, 46, 127-132.	1.8	16
579	54-Year-Old Woman With Fatigue, Back Pain, and Hypercalcemia. <i>Mayo Clinic Proceedings</i> , 2009, 84, e9-e12.	1.4	0
580	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	1.4	389
581	Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2009, 360, 2645-2654.	13.9	168
582	Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. <i>Anti-Cancer Drugs</i> , 2009, 20, 259-266.	0.7	19
583	Stem cell transplantation for multiple myeloma. <i>Current Opinion in Oncology</i> , 2009, 21, 162-170.	1.1	19
584	The Importance of Complete Response in Outcomes in Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 465-472.	1.0	9
585	Integrating Novel Therapies in the Transplant Paradigm. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 479-484.	1.0	3
586	Hematopoietic Progenitor Cells: Autologous Transplantation. , 0, , 521-541.		1
587	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	0.6	92
588	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009, 113, 3383-3391.	0.6	106
589	Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. <i>Blood</i> , 2009, 113, 733-743.	0.6	46
590	Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. <i>Blood</i> , 2009, 113, 5720-5726.	0.6	697
591	RAR α ±2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. <i>Blood</i> , 2009, 114, 600-607.	0.6	20
592	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2009, 114, 518-521.	0.6	130
593	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009, 114, 5436-5443.	0.6	122
594	Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 845-859.		0

#	ARTICLE	IF	CITATIONS
595	Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 961-970.	2.3	13
596	Bendamustine in patients with relapsed or refractory multiple myeloma. <i>European Journal of Medical Research</i> , 2010, 15, 13.	0.9	34
597	THE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA. <i>Acta Clinica Belgica</i> , 2010, 65, 252-264.	0.5	0
598	The Prognostic Value of F-18 Fluorodeoxyglucose Bone Marrow Uptake in Patients With Recent Diagnosis of Multiple Myeloma. <i>Clinical Nuclear Medicine</i> , 2010, 35, 1-5.	0.7	21
600	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	1.7	101
601	Successful stem-cell mobilization and transplantation using plerixafor in a patient with a germ cell tumor. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2010, 3, 203-205.	0.6	10
602	A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. <i>Blood</i> , 2010, 115, 1113-1120.	0.6	271
603	Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM). <i>Blood</i> , 2010, 115, 32-37.	0.6	152
604	Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. <i>Blood</i> , 2010, 115, 2348-2353.	0.6	42
605	Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. <i>Blood</i> , 2010, 115, 3655-3663.	0.6	113
606	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	0.6	87
607	Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. <i>Blood</i> , 2010, 116, 2033-2039.	0.6	43
608	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	0.6	101
609	Refractory Evans Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma: Management with a Second Transplantation. <i>Internal Medicine</i> , 2010, 49, 683-687.	0.3	4
610	Total therapy-based treatment for multiple myeloma—a single center experience. <i>Annals of Hematology</i> , 2010, 89, 53-59.	0.8	4
611	Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). <i>Annals of Hematology</i> , 2010, 89, 489-497.	0.8	12
612	Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. <i>Annals of Hematology</i> , 2010, 89, 579-584.	0.8	14
613	Monoclonal gammopathy of undetermined significance related pyoderma gangrenosum successfully treated with autologous peripheral blood stem cell transplantation. <i>Annals of Hematology</i> , 2010, 89, 823-824.	0.8	7

#	ARTICLE	IF	CITATIONS
614	Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. <i>Annals of Hematology</i> , 2010, 89, 905-912.	0.8	17
615	Correlation Between Survival and Number of Mobilized CD34+ Cells in Patients with Multiple Myeloma or Waldenström Macroglobulinemia. <i>Pathology and Oncology Research</i> , 2010, 16, 583-587.	0.9	4
616	Treatment of newly diagnosed multiple myeloma: advances in current therapy. <i>Medical Oncology</i> , 2010, 27, 14-24.	1.2	10
617	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , 2010, 27, 1-6.	1.2	34
618	Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience. <i>International Journal of Hematology</i> , 2010, 92, 518-523.	0.7	6
619	Plerixafor: A Peripheral Blood Stem Cell Mobilizer. <i>Pharmacotherapy</i> , 2010, 30, 485-492.	1.2	38
620	ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with <i>de novo</i> multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 474-483.	1.1	20
621	Multiple myeloma: chemotherapy or transplantation in the era of new drugs. <i>European Journal of Haematology</i> , 2010, 84, 379-390.	1.1	36
622	Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. <i>European Journal of Haematology</i> , 2010, 85, 181-191.	1.1	18
623	Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 85, 416-423.	1.1	43
624	Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. <i>Cancer</i> , 2010, 116, 640-646.	2.0	3
625	Increased risk of citrate reactions in patients with multiple myeloma during peripheral blood stem cell leukapheresis. <i>Journal of Clinical Apheresis</i> , 2010, 25, 188-194.	0.7	7
626	A Phase II study of ¹⁵³ Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2010, 85, 409-413.	2.0	22
627	Targeted therapy in haematological malignancies. <i>Journal of Pathology</i> , 2010, 220, 404-418.	2.1	29
628	Frequency of altered monoclonal protein production at relapse of multiple myeloma. <i>British Journal of Haematology</i> , 2010, 148, 659-661.	1.2	15
629	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2010, 148, 853-858.	1.2	10
630	Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. <i>British Journal of Haematology</i> , 2010, 150, 313-325.	1.2	42
631	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. <i>British Journal of Haematology</i> , 2010, 150, 326-333.	1.2	57

#	ARTICLE	IF	CITATIONS
632	Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K. <i>Gene Therapy</i> , 2010, 17, 389-399.	2.3	45
633	Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. <i>Bone Marrow Transplantation</i> , 2010, 45, 63-68.	1.3	80
634	CR represents an early index of potential long survival in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2010, 45, 498-504.	1.3	46
635	Management of multiple myeloma in older adults. , 0, , 288-296.		0
636	Anti-angiogenesis therapies: their potential in cancer management. <i>OncoTargets and Therapy</i> , 2010, 3, 69.	1.0	39
637	Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. <i>Neoplasia</i> , 2010, 57, 111-117.	0.7	17
638	Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. <i>The Korean Journal of Hematology</i> , 2010, 45, 183.	0.7	13
639	Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma – does it matter?. <i>Clinical Pharmacology: Advances and Applications</i> , 2010, 2, 71.	0.8	1
640	Solitary Intracranial Plasmacytoma Located in the Spheno-Clival Region Mimicking Chordoma: A Case Report. <i>Journal of International Medical Research</i> , 2010, 38, 1868-1875.	0.4	20
641	Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 830-834.	0.8	165
642	Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms. <i>Journal of Clinical Oncology</i> , 2010, 28, 3023-3027.	0.8	39
643	Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents. <i>Journal of Clinical Oncology</i> , 2010, 28, 2612-2624.	0.8	186
644	Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 243-251.	0.6	15
645	Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 236-242.	0.6	19
646	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v155-v157.	0.6	51
647	A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. <i>Annals of Oncology</i> , 2010, 21, 1898-1904.	0.6	22
648	Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. <i>Cancer Biology and Therapy</i> , 2010, 10, 1201-1214.	1.5	21
649	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. <i>Oncologist</i> , 2010, 15, 6-25.	1.9	85

#	ARTICLE	IF	CITATIONS
650	Ultra High-Risk Myeloma. Hematology American Society of Hematology Education Program, 2010, 2010, 489-493.	0.9	64
651	Rapid control of previously untreated multiple myeloma with bortezomib+“lenalidomide+“dexamethasone (BLD). Hematology, 2010, 15, 70-73.	0.7	17
652	Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 2010, 21, 325-330.	0.6	386
653	Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. Bone Marrow Transplantation, 2010, 45, 1625-1630.	1.3	8
654	Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 290-296.	0.2	2
655	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 353-360.	0.2	4
656	Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 424-442.	0.2	26
657	Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica, 2010, 95, 1150-1157.	1.7	154
658	Increased adenosine triphosphate production by peripheral blood CD4+ cells in patients with hematologic malignancies treated with stem cell mobilization agents. Human Immunology, 2010, 71, 652-658.	1.2	7
659	“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 70-77.	2.0	7
660	Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 395-402.	2.0	55
661	Poor Mobilization of Hematopoietic Stem Cells” Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 490-499.	2.0	232
662	Combined Submyeloablative and Myeloablative Dose Intense Melphalan Results in Satisfactory Responses with Acceptable Toxicity in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2010, 16, 1402-1410.	2.0	5
663	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. Journal of Clinical Oncology, 2010, 28, 1209-1214.	0.8	144
664	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, The, 2010, 376, 2075-2085.	6.3	770
665	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC) Tj ETQq1 1 0.784314 rgBT/Ovelo	6.3	505
666	Multiple myeloma “ current issues and controversies. Cancer Treatment Reviews, 2010, 36, S3-S11.	3.4	38
667	Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 458-463.	0.2	29

#	ARTICLE	IF	CITATIONS
668	Efficacy and outcome of autologous transplantation in rare myelomas. <i>Haematologica</i> , 2010, 95, 2126-2133.	1.7	51
669	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. <i>Lancet Oncology</i> , The, 2010, 11, 29-37.	5.1	882
670	Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. <i>Lancet Oncology</i> , The, 2010, 11, 973-982.	5.1	106
671	Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4621-4629.	0.8	512
673	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	0.6	49
674	Matrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway. <i>Leukemia and Lymphoma</i> , 2010, 51, 1337-1346.	0.6	30
675	Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple Myeloma. <i>Cancer Investigation</i> , 2011, 29, 214-219.	0.6	8
676	Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. <i>Blood</i> , 2011, 117, 788-797.	0.6	148
677	Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1281-1289.	0.6	7
678	Managing multiple myeloma in the elderly: are we making progress?. <i>Expert Review of Hematology</i> , 2011, 4, 301-315.	1.0	6
679	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	3.3	51
680	Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 1898-1906.	0.8	126
681	Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls. <i>Leukemia and Lymphoma</i> , 2011, 52, 436-443.	0.6	13
682	MyÅ©lome multiple. , 2011, , 779-791.		0
683	Inpatient Rehabilitation in Persons With Multiple Myelomaâ€Associated Fractures: An Analysis of 8 Consecutive Inpatient Admissions. <i>PM and R</i> , 2011, 3, 78-84.	0.9	7
684	From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1015-1028.	1.9	5
685	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 412-420.	2.0	40
686	Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1146-1153.	2.0	110

#	ARTICLE	IF	CITATIONS
687	Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1638-1645.	2.0	59
688	Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1765-1774.	2.0	53
689	Pomalidomide therapy for myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 691-700.	1.9	29
690	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	5.1	263
691	Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma. <i>Stem Cells and Cloning: Advances and Applications</i> , 2011, 4, 11.	2.3	2
692	Advances in the Autologous and Allogeneic Transplantation Strategies for Multiple Myeloma. <i>Cancer Control</i> , 2011, 18, 258-267.	0.7	17
693	Generation of a Predictive Melphalan Resistance Index by Drug Screen of B-Cell Cancer Cell Lines. <i>PLoS ONE</i> , 2011, 6, e19322.	1.1	18
694	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 415-429.	0.2	4
695	Free Light Chains of Immunoglobulin as a Prognostic Factor for Some Plasmaproliferative Diseases. <i>Journal of Medical Biochemistry</i> , 2011, 30, 293-301.	0.7	1
697	Maintenance treatment of multiple myeloma: evidence from recent clinical trials. <i>Clinical Investigation</i> , 2011, 1, 837-848.	0.0	0
698	Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. <i>Blood</i> , 2011, 117, 2121-2128.	0.6	15
699	Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. <i>Blood</i> , 2011, 117, 3041-3044.	0.6	109
700	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	0.6	183
701	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
702	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	0.6	113
703	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). <i>Blood</i> , 2011, 118, 4086-4092.	0.6	173
704	Approach to the treatment of multiple myeloma: a clash of philosophies. <i>Blood</i> , 2011, 118, 3205-3211.	0.6	137
705	Re-transplantation after bortezomib-based therapy. <i>British Journal of Haematology</i> , 2011, 153, 666-668.	1.2	8

#	ARTICLE	IF	CITATIONS
706	Guidelines for the diagnosis and management of multiple myeloma 2011. <i>British Journal of Haematology</i> , 2011, 154, 32-75.	1.2	252
707	Clinical impact of chromosomal aberrations in multiple myeloma. <i>Journal of Internal Medicine</i> , 2011, 269, 137-147.	2.7	35
708	Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide) Tj ETQq0 0 0 ggBT /Overlock 10 Tf +100 hematopoietic graft function. <i>Transfusion</i> , 2011, 51, 1995-2000.	0.8	26
709	Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. <i>Transfusion</i> , 2011, 51, 1300-1313.	0.8	18
710	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. <i>Leukemia</i> , 2011, 25, 689-696.	3.3	104
711	Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. <i>Bone Marrow Transplantation</i> , 2011, 46, 52-58.	1.3	118
712	Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. <i>Bone Marrow Transplantation</i> , 2011, 46, 64-69.	1.3	124
713	Emerging therapies for the treatment of relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 1-15.	1.1	70
714	In and out of the niche: perspectives in mobilization of hematopoietic stem cells. <i>Experimental Hematology</i> , 2011, 39, 723-729.	0.2	56
715	Multiple myeloma patients at peripheral blood stem cell harvest: Restricted usage of TCR beta variable families. <i>Clinical Immunology</i> , 2011, 138, 67-76.	1.4	1
716	CD4+ CD28+ lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft. <i>Cytotherapy</i> , 2011, 13, 987-992.	0.3	6
717	Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 985-997.	2.0	34
718	Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. <i>Annals of Hematology</i> , 2011, 90, 423-428.	0.8	28
719	First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. <i>Advances in Therapy</i> , 2011, 28, 304-310.	1.3	54
720	Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 104-112.	1.2	11
721	Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 57-65.	2.0	137
722	The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. <i>Cancer</i> , 2011, 117, 1884-1890.	2.0	13
723	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. <i>Leukemia Research</i> , 2011, 35, 899-903.	0.4	20

#	ARTICLE	IF	CITATIONS
724	Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 510-515.	1.3	22
725	High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 1156-1157.	1.3	1
726	Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1253-1263.	3.2	72
728	Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. <i>Blood Cancer Journal</i> , 2011, 1, e39-e39.	2.8	71
729	Evolving role of high dose stem cell therapy in multiple myeloma. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2011, 32, 17.	0.1	5
731	Total Marrow Irradiation: A New Ablative Regimen as Part of Tandem Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 174-182.	3.2	56
732	Bortezomib-Dexamethasone or Vincristine-Doxorubicin-Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients. <i>Journal of International Medical Research</i> , 2011, 39, 1975-1984.	0.4	11
733	Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 1-9.	0.6	2
734	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2011, 29, 3016-3022.	0.8	171
735	High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. <i>British Journal of Cancer</i> , 2011, 105, 970-974.	2.9	17
736	Treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 479-491.	12.5	239
737	Greffe de cellules souches h�matopo�tiques. , 2011, , 600-606.		1
738	Stem Cell Transplantation for Multiple Myeloma: Current and Future Status. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 191-196.	0.9	30
739	<i>Ex Vivo</i> Graft Purging and Expansion of Autologous Blood Progenitor Cell Products from Patients with Multiple Myeloma. <i>Cancer Research</i> , 2011, 71, 5040-5049.	0.4	14
740	Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. <i>Bone Marrow Transplantation</i> , 2011, 46, 523-528.	1.3	70
741	Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. <i>Bone Marrow Transplantation</i> , 2011, 46, 943-949.	1.3	57
742	Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. <i>Bone Marrow Transplantation</i> , 2011, 46, 350-355.	1.3	55
743	The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. <i>Bone Marrow Transplantation</i> , 2011, 46, 1210-1218.	1.3	7

#	ARTICLE	IF	CITATIONS
745	THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011047.	0.5	9
746	UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012069.	0.5	6
747	Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions. Clinical and Developmental Immunology, 2012, 2012, 1-28.	3.3	28
748	Growth factor plus preemptive (â€œjust-in-timeâ€™) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplantation, 2012, 47, 1403-1408.	1.3	45
749	Role of autologous bone marrow transplant in multiple myeloma. Current Opinion in Oncology, 2012, 24, 733-741.	1.1	7
750	Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: whatâ€™s new?. Journal of Comparative Effectiveness Research, 2012, 1, 57-70.	0.6	0
751	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica, 2012, 97, 64-72.	1.7	109
752	Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2012, 47, 516-521.	1.3	10
753	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opinion on Biological Therapy, 2012, 12, 1449-1462.	1.4	18
754	Feasibility of autologous hematopoietic stem cell transplant in patients aged â‰¥70 years with multiple myeloma. Leukemia and Lymphoma, 2012, 53, 118-122.	0.6	74
755	Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1782-1791.	13.9	1,022
756	F2A sequence linking MGMP140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Therapy, 2012, 19, 802-810.	2.2	10
757	The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells. Molecular Cancer Therapeutics, 2012, 11, 1781-1788.	1.9	52
758	Advanced prostate cancerâ€™a case for adjuvant differentiation therapy. Nature Reviews Urology, 2012, 9, 595-602.	1.9	32
759	Monoclonal antibody-based immunotherapy for multiple myeloma. Immunotherapy, 2012, 4, 919-938.	1.0	8
760	Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma. Therapeutic Advances in Hematology, 2012, 3, 81-88.	1.1	0
761	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1209-1222.	1.5	9
762	Targeting the Proteasome With Bortezomib in Multiple Myeloma. American Journal of Therapeutics, 2012, 19, 133-144.	0.5	13

#	ARTICLE	IF	CITATIONS
763	Stem cell transplantation for multiple myeloma: current and future status. <i>Hematology</i> , 2012, 17, s117-s120.	0.7	11
764	Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. <i>Journal of Chemotherapy</i> , 2012, 24, 167-172.	0.7	8
765	Cancer stem cells. <i>Current Opinion in Oncology</i> , 2012, 24, 170-175.	1.1	9
766	Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. <i>Haematologica</i> , 2012, 97, 616-621.	1.7	19
767	Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. <i>Haematologica</i> , 2012, 97, 442-450.	1.7	144
768	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2012, 120, 9-19.	0.6	305
769	Advances in stem cell mobilization. <i>Blood Reviews</i> , 2012, 26, 267-278.	2.8	98
770	High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. <i>Blood</i> , 2012, 120, 4445-4446.	0.6	38
771	Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012, 89, 328-335.	1.1	15
773	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2946-2955.	0.8	735
774	Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw: a longitudinal cohort study. <i>Supportive Care in Cancer</i> , 2012, 20, 2969-2975.	1.0	3
775	ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. <i>FEBS Letters</i> , 2012, 586, 4311-4318.	1.3	30
776	Myeloma Kidney: Improving Clinical Outcomes?. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 342-351.	0.6	11
778	Development of novel CXCR4-based therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 341-353.	1.9	78
779	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
780	Peripheral Blood CD34+ Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 763-772.	2.0	48
781	Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S27-S32.	2.0	21
782	High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1055-1060.	2.0	19

#	ARTICLE	IF	CITATIONS
783	Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1128-1135.	2.0	59
784	Melphalan 180 mg/m ² Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m ² or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1455-1461.	2.0	14
785	Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma – comparison between two different induction regimens. <i>Clinical Transplantation</i> , 2012, 26, E549-54.	0.8	1
786	Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 842-853.	1.1	10
787	Myeloablative Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation. <i>Medical Radiology</i> , 2012, , 669-683.	0.0	0
788	Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. <i>Bone Marrow Transplantation</i> , 2012, 47, 18-23.	1.3	20
789	Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. <i>Bone Marrow Transplantation</i> , 2012, 47, 1312-1317.	1.3	23
790	Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 325-329.	0.2	8
791	Thalidomide-induced acute cholestatic hepatitis: Case report and review of the literature. <i>Gastroenterology & Hepatology</i> , 2012, 35, 560-566.	0.2	12
792	Who should be really considered as a poor mobilizer in the plerixafor era?. <i>Transfusion and Apheresis Science</i> , 2012, 47, 27-32.	0.5	11
793	Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2012, 36, S13-S18.	0.4	8
794	Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. <i>Medical Oncology</i> , 2012, 29, 2191-2199.	1.2	20
795	Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population. <i>International Journal of Hematology</i> , 2012, 96, 477-484.	0.7	1
797	Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1191-1203.	2.0	69
798	Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. <i>Leukemia and Lymphoma</i> , 2012, 53, 2444-2448.	0.6	8
799	Plasma Cell Disorders. , 2012, , 1233-1243.		1
800	Autologous stem cell transplantation in Kuwait cancer control centre: Review of infections in the first thirty days post-transplant. <i>Journal of Hematological Malignancies</i> , 2012, 2, .	0.0	0
801	The Current Role of Stem Cell Transplantation in Multiple Myeloma. , 0, , .		0

#	ARTICLE	IF	CITATIONS
802	Epidemiology, Biology, and Outcome in Multiple Myeloma Patients in different Geographical Areas of the World. <i>Orthodontic Journal of Nepal</i> , 2012, 1, 20-32.	0.0	4
803	Optimizing stem cell collection through CXCR4 antagonists. <i>Frontiers in Bioscience - Scholar</i> , 2012, S4, 611-619.	0.8	3
804	Tandem autologous stem cell transplantation in multiple myeloma after high-dose chemotherapy with two separate collections: single institution experience. <i>Neoplasma</i> , 2012, 59, 551-558.	0.7	0
806	Emergence of central nervous system myeloma in the era of novel agents. <i>Hematological Oncology</i> , 2012, 30, 170-174.	0.8	34
807	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 948-952.	2.0	63
808	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. <i>Cancer</i> , 2012, 118, 2507-2515.	2.0	39
809	Durable remission with salvage second autotransplants in patients with multiple myeloma. <i>Cancer</i> , 2012, 118, 3549-3555.	2.0	69
810	Pancreatic Involvement by Plasma Cell Neoplasms. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 157-167.	0.6	16
811	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2012, 91, 1161-1174.	0.8	40
812	Extramedullary plasmacytoma of the small intestine: Clinical features, diagnosis and treatment. <i>Journal of Digestive Diseases</i> , 2012, 13, 10-18.	0.7	25
813	Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. <i>American Journal of Kidney Diseases</i> , 2012, 59, 786-794.	2.1	174
814	Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. <i>Transfusion</i> , 2012, 52, 2375-2381.	0.8	27
815	Genetic variations in multiple myeloma II: association with effect of treatment. <i>European Journal of Haematology</i> , 2012, 88, 93-117.	1.1	28
816	Effect of time to infusion of autologous stem cells (24 vs. 48h) after high-dose melphalan in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2012, 89, 145-150.	1.1	10
817	Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2012, 89, 228-235.	1.1	11
818	“Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment?” <i>Leukemia Research</i> , 2012, 36, 677-681.	0.4	14
819	Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis. <i>Leukemia Research</i> , 2012, 36, 1016-1021.	0.4	43
820	Bortezomib salvage followed by a phase II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. <i>British Journal of Haematology</i> , 2012, 157, 553-563.	1.2	21

#	ARTICLE	IF	CITATIONS
821	Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. <i>British Journal of Haematology</i> , 2012, 158, 91-98.	1.2	97
822	Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. <i>Clinical Transplantation</i> , 2012, 26, 117-122.	0.8	27
823	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012, 118, 1585-1592.	2.0	106
824	Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 78-88.	2.0	120
825	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. <i>Annals of Hematology</i> , 2012, 91, 249-256.	0.8	15
826	Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 419-426.	0.8	11
827	Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. <i>Bone Marrow Transplantation</i> , 2013, 48, 1279-1284.	1.3	43
828	Peripheral blood stem cell mobilization in multiple myeloma patients treated in the novel therapy era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. <i>Journal of Clinical Apheresis</i> , 2013, 28, 359-367.	0.7	25
829	Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 445-449.	2.0	62
830	Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. <i>Bone Marrow Transplantation</i> , 2013, 48, 1444-1449.	1.3	32
831	A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 831-837.	2.0	29
832	Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. <i>Supportive Care in Cancer</i> , 2013, 21, 2437-2442.	1.0	21
833	Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. <i>International Journal of Hematology</i> , 2013, 98, 186-196.	0.7	8
834	Salvage Second Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
835	Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1381-1392.	2.0	61
836	Challenges in multiple myeloma diagnosis and treatment. <i>Leukemia Supplements</i> , 2013, 2, S3-S9.	0.1	9
837	Role of thalidomide in the treatment of patients with multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S14-S22.	2.0	22
838	Evolving Strategies in the Initial Treatment of Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 592-601.	0.8	5

#	ARTICLE	IF	CITATIONS
839	Managing multiple myeloma patients with renal failure. Hong Kong Journal of Nephrology, 2013, 15, 62-67.	0.0	1
840	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation, 2013, 19, 69-74.	2.0	60
841	Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncology, 2013, 9, 939-948.	1.1	3
842	Frontline Therapy for Multiple Myeloma: A Concise Review of the Evidence Based on Randomized Clinical Trials. Cancer Investigation, 2013, 31, 529-537.	0.6	10
843	Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer, 2013, 119, 4308-4315.	2.0	12
844	Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e571-e581.	5.1	37
845	Allogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S330-S348.	0.2	5
846	Bortezomib-containing induction regimens in transplant-eligible myeloma patients. Cancer, 2013, 119, 4119-4128.	2.0	36
847	Autologous retransplantation for patients with recurrent multiple myeloma. Cancer, 2013, 119, 2438-2446.	2.0	51
849	A population-based analysis of the effect of autologous hematopoietic cell transplant in the treatment of multiple myeloma. Leukemia and Lymphoma, 2013, 54, 1671-1676.	0.6	7
850	Phase I / II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Science, 2013, 104, 912-919.	1.7	18
851	Multiple myeloma – current status and future directions. Expert Opinion on Orphan Drugs, 2013, 1, 793-804.	0.5	0
852	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi133-vi137.	0.6	187
853	Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1517-1527.	1.5	17
854	CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion, 2013, 53, 1024-1032.	0.8	29
855	Diagnosis and Treatment of Multiple Myeloma. , 2013, , 637-663.		2
856	Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States. Biology of Blood and Marrow Transplantation, 2013, 19, 1459-1464.	2.0	25
857	Role of Consolidation Therapy in Transplant Eligible Multiple Myeloma Patients. Seminars in Oncology, 2013, 40, 610-617.	0.8	10

#	ARTICLE	IF	CITATIONS
858	Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 129-137.	2.0	16
859	Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 25-31.	0.2	5
860	Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 654-659.	2.4	34
861	A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 56-61.	2.0	21
862	The use of granulocyte colony stimulating factor (G-CSF) (filgrastim) alone in the mobilization of stem cell in the autologous stem cell transplantation. <i>Transfusion and Apheresis Science</i> , 2013, 49, 97-99.	0.5	6
863	Pharmacoeconomics of Hematopoietic Stem Cell Mobilization: An Overview of Current Evidence and Gaps in the Literature. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1301-1309.	2.0	23
864	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
865	Continuous treatment in multiple myeloma: The future?. <i>Transfusion and Apheresis Science</i> , 2013, 49, 147-150.	0.5	5
866	Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic Factors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 32-41.	0.2	14
867	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1615-1624.	2.0	99
868	Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. <i>British Journal of Haematology</i> , 2013, 160, 199-206.	1.2	13
869	Phase I trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2013, 160, 321-330.	1.2	48
870	Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hematology and Oncology</i> , 2013, 6, 2.	6.9	42
871	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1658-1664.	0.6	63
872	Multiple myeloma: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 225-235.	2.0	105
873	Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2219-2225.	0.6	22
874	Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 344-356.	2.0	90
875	A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis. <i>Acta Haematologica</i> , 2013, 130, 7-15.	0.7	5

#	ARTICLE	IF	CITATIONS
876	Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation, 2013, 48, 568-573.	1.3	59
877	Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT. Bone Marrow Transplantation, 2013, 48, 425-432.	1.3	24
878	Evolving therapeutic paradigms for multiple myeloma: back to the future. Leukemia and Lymphoma, 2013, 54, 451-463.	0.6	15
879	Multiple myeloma. BMJ, The, 2013, 346, f3863-f3863.	3.0	64
880	Cellular immunotherapy for plasma cell myeloma. Bone Marrow Transplantation, 2013, 48, 1377-1386.	1.3	8
881	Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study. Journal of Clinical Oncology, 2013, 31, 2540-2547.	0.8	372
882	Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opinion on Investigational Drugs, 2013, 22, 619-634.	1.9	17
883	Solitary clival plasmocytomas: Misleading clinical and radiological features of a rare pathology with a specific biological behaviour. Acta Neurochirurgica, 2013, 155, 1849-1856.	0.9	21
884	Solitary nonchordomatous lesions of the clival bone: differential diagnosis and current therapeutic strategies. Neurosurgical Review, 2013, 36, 513-522.	1.2	15
885	Organ engineering “ combining stem cells, biomaterials, and bioreactors to produce bioengineered organs for transplantation. BioEssays, 2013, 35, 163-172.	1.2	109
886	Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction. Hematology, 2013, 18, 341-347.	0.7	1
887	Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma. Oncology, 2013, 85, 223-227.	0.9	15
888	External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 696-699.	2.2	11
889	Current approaches to the initial treatment of symptomatic multiple myeloma. International Journal of Hematologic Oncology, 2013, 2, 61-70.	0.7	11
890	Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leukemia and Lymphoma, 2013, 54, 2200-2204.	0.6	39
891	Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients. Bone Marrow Transplantation, 2013, 48, 319-320.	1.3	2
892	Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplantation, 2013, 48, 1543-1547.	1.3	30
893	Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplantation, 2013, 48, 562-567.	1.3	66

#	ARTICLE	IF	CITATIONS
894	Incident hyperglycemia, parenteral nutrition administration and adverse outcomes in patients with myeloma admitted for initial auto-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1117-1122.	1.3	4
895	Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2013, 48, 1179-1184.	1.3	14
896	Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. <i>Bone Marrow Transplantation</i> , 2013, 48, 1537-1542.	1.3	20
897	<i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 3019-3031.	3.2	86
898	Synthesis, Characterization and <i>In Vitro</i> Drug Release of Melphalan Magnetic Microspheres. <i>Journal of Nano Research</i> , 2013, 22, 31-40.	0.8	0
899	Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients. <i>Journal of Clinical Apheresis</i> , 2013, 28, 395-403.	0.7	14
900	Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization. <i>American Journal of Hematology</i> , 2013, 88, 754-757.	2.0	22
901	Second autologous transplant as salvage therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 565-572.	1.2	37
902	Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre. <i>Internal Medicine Journal</i> , 2013, 43, 130-137.	0.5	2
903	Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. <i>Blood Cancer Journal</i> , 2013, 3, e121-e121.	2.8	57
904	Stem cell transplantation for multiple myeloma: current and future status. <i>Leukemia Supplements</i> , 2013, 2, S10-S14.	0.1	3
905	Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 43-47.	0.3	0
906	Evaluation of the Feasibility and Efficacy of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma. <i>Internal Medicine</i> , 2013, 52, 63-70.	0.3	37
907	Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. <i>Blood</i> , 2013, 121, 4647-4654.	0.6	128
908	Transplants for the elderly in myeloma. <i>Blood</i> , 2013, 122, 1332-1334.	0.6	7
910	Multiple myeloma: the bone marrow microenvironment and its relation to treatment. <i>British Journal of Biomedical Science</i> , 2013, 70, 110-120.	1.2	47
911	Autologous hematopoietic stem cell transplantation and maintenance therapy for multiple myeloma. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 71-83.	0.7	3
912	Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2013, 28, 80.	1.1	4

#	ARTICLE	IF	CITATIONS
913	Controversies in Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma. , 2013, , .		2
914	Multiple Myeloma in Horses, Dogs and Cats: A Comparative Review Focused on Clinical Signs and Pathogenesis. , 2013, , .		4
917	Multiple Myeloma: An Update. Oman Medical Journal, 2013, 28, 3-11.	0.3	33
918	The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction. Journal of Hematological Malignancies, 2013, 3, .	0.0	0
919	Peripheral Blood Progenitor Cells Mobilization in Patients with Multiple Myeloma. Journal of Stem Cell Research & Therapy, 2014, 04, .	0.3	0
920	Autologous Stem Cell Transplant in Multiple Myeloma: Excellent Safety and Efficacy Possible in a Non University Hospital of Developing Country. Journal of Hematology & Thromboembolic Diseases, 2014, 02, .	0.1	0
921	Autologous stem cell transplantation for multiple myeloma. Journal of Hematopoietic Cell Transplantation, 2014, 3, 64-78.	0.1	0
923	Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma. Cancer Treatment Communications, 2014, 2, 34-47.	0.4	28
924	Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. Journal of Clinical Oncology, 2014, 32, 2125-2132.	0.8	22
926	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplantation, 2014, 49, 201-205.	1.3	20
927	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia, 2014, 28, 2060-2065.	3.3	109
928	Advance care planning among hematopoietic cell transplant patients and bereaved caregivers. Bone Marrow Transplantation, 2014, 49, 1317-1322.	1.3	23
929	Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation. Bone Marrow Transplantation, 2014, 49, 1042-1045.	1.3	22
930	A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program. Bone Marrow Transplantation, 2014, 49, 751-755.	1.3	17
931	Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplantation, 2014, 49, 422-425.	1.3	3
932	All transplantation-eligible patients with myeloma should receive ASCT in first response. Hematology American Society of Hematology Education Program, 2014, 2014, 250-254.	0.9	13
933	Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplantâ€”A Prospective Phase II Study. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S16835.	0.6	5
934	Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future. BioMed Research International, 2014, 2014, 1-7.	0.9	17

#	ARTICLE	IF	CITATIONS
935	Impact of Informative Censoring on the Kaplan-Meier Estimate of Progression-Free Survival in Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2014, 32, 3068-3074.	0.8	44
936	Inhibition of Nek2 by Small Molecules Affects Proteasome Activity. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	19
937	Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. <i>Leukemia and Lymphoma</i> , 2014, 55, 2850-2857.	0.6	17
938	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	0.9	25
940	Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 368-378.	1.2	18
941	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
942	High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 1131-1144.	0.9	16
943	<scp>U</scp>nited <scp>K</scp>ingdom <scp>M</scp>yeloma <scp>F</scp>orum (<scp>UKMF</scp>) position statement on the use of bendamustine in myeloma. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 20-28.	0.7	10
944	A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2013-2017.	0.6	15
945	Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. <i>Advances in Hematology</i> , 2014, 2014, 1-12.	0.6	11
946	Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation. <i>Acta Haematologica</i> , 2014, 132, 226-232.	0.7	6
947	Optimal Dosing of Melphalan As High-Dose Therapy Before Autologous Hematopoietic Stem Cell Transplantation in Myeloma Patients With Solitary Kidney: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e59-e63.	0.2	3
948	Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high-dose etoposide stem cell mobilization regimens with N-terminal pro-B-type natriuretic peptide. <i>Transfusion and Apheresis Science</i> , 2014, 50, 46-52.	0.5	12
949	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
950	The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 291-296.	0.2	12
952	Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2014, 165, 777-785.	1.2	30
953	Advances in stem cell mobilization. <i>Blood Reviews</i> , 2014, 28, 31-40.	2.8	122
954	High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: A Single Institution Experience at All India Institute of Medical Sciences, New Delhi, Using Non-Cryopreserved Peripheral Blood Stem Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 140-147.	0.2	31

#	ARTICLE	IF	CITATIONS
955	The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 469-479.	3.2	76
956	Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 219-222.	1.3	8
957	The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF. <i>Transfusion and Apheresis Science</i> , 2014, 50, 71-74.	0.5	1
959	Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 295-308.	2.0	305
960	Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines. <i>Transfusion</i> , 2014, 54, 509-515.	0.8	2
961	Multiple myeloma: 2014 Update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 998-1009.	2.0	148
962	Optimizing the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 686-688.	12.5	0
963	Preliminary dosimetric evaluation of 166 Ho-TTHMP for human based on biodistribution data in rats. <i>Applied Radiation and Isotopes</i> , 2014, 94, 260-265.	0.7	20
964	Bortezomib and lenalidomide as front-line therapy for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2024-2031.	0.6	17
965	Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 815-827.	0.9	2
966	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.2	7
967	Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma. <i>Cytotherapy</i> , 2014, 16, 1584-1589.	0.3	12
968	State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. <i>European Journal of Radiology</i> , 2014, 83, 2203-2223.	1.2	78
969	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Tj ETQq1 1 0.784314 rgBT /Overl... 15, 874-885.	0.1	139
970	Multiple Myeloma in the Older Adult: Better Prospects, More Challenges. <i>Journal of Clinical Oncology</i> , 2014, 32, 2531-2540.	0.8	61
971	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 500-505.	1.2	81
972	Initial treatment of transplant-eligible patients in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 43-53.	1.0	14
973	Controversies in Multiple Myeloma: to Transplant or Not?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 360-367.	1.2	4

#	ARTICLE	IF	CITATIONS
974	Autologous hematopoietic cell transplantation: An update for clinicians. <i>Annals of Medicine</i> , 2014, 46, 619-632.	1.5	14
975	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
976	Maintenance Therapy for Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 839-859.	0.9	14
977	Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study. <i>Annals of Hematology</i> , 2014, 93, 1571-1577.	0.8	3
979	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. <i>Blood Reviews</i> , 2014, 28, 75-86.	2.8	52
980	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	13.9	683
981	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 222-228.	2.0	36
982	Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 148-154.	0.2	13
983	Outcomes of autologous transplantation for multiple myeloma according to different induction regimens. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 19-24.	0.7	9
984	Low Uptake of Upfront Autologous Transplantation for Myeloma in a Jurisdiction With Universal Health Care Coverage: A Population-Based Patterns of Care Study in Australia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 61-67.	0.2	5
985	Safety of Outpatient Autologous Hematopoietic Cell Transplantation (AuHCT) for Multiple Myeloma and Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S114.	2.0	3
986	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
987	Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 761-766.	1.3	19
988	Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 128-136.	2.3	47
989	Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers. <i>Haematologica</i> , 2014, 99, 408-416.	1.7	54
990	How we manage autologous stem cell transplantation for patients with multiple myeloma. <i>Blood</i> , 2014, 124, 882-890.	0.6	85
991	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014, 124, 907-912.	0.6	111
992	Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2014, 29, 305-310.	0.7	6

#	ARTICLE	IF	CITATIONS
993	Maintenance therapy for multiple myeloma after an autologous transplant: what have we learned?. International Journal of Hematologic Oncology, 2014, 3, 1-3.	0.7	0
994	Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. Journal of Clinical Apheresis, 2014, 29, 293-298.	0.7	4
995	Similar dynamics of intraapheresis autologous <scp>CD</scp>34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixafor. Transfusion, 2014, 54, 3131-3137.	0.8	4
996	Light Chain Escape Multiple Myeloma Complicated with Catastrophic Extramedullary Plasmacytoma Following Novel Agent Treatment. Journal of Cancer Research and Practice, 2014, 1, 39-45.	0.2	0
997	Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion, 2015, 55, 275-283.	0.8	38
998	Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. Clinical Case Reports (discontinued), 2015, 3, 370-375.	0.2	4
999	Bendamustine in multiple myeloma. European Journal of Haematology, 2015, 95, 377-388.	1.1	23
1000	Mobilization and Transplantation Patterns of Autologous Hematopoietic Stem Cells in Multiple Myeloma and Non-Hodgkin Lymphoma. Cancer Control, 2015, 22, 87-94.	0.7	5
1001	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers and Therapy, 2015, 3, 47-68.	0.2	14
1002	Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. British Journal of Haematology, 2015, 171, 453-462.	1.2	27
1003	Allogeneic stem cell transplantation for multiple myeloma. Journal of Hematopoietic Cell Transplantation, 2015, 4, 1-8.	0.1	0
1004	Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. Transfusion, 2015, 55, 2142-2148.	0.8	10
1005	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma. Chinese Medical Journal, 2015, 128, 1215-1222.	0.9	16
1006	Should Vital Signs be Routinely Obtained Prior to Intravenous Chemotherapy? Results from a 2-Center Study. Cancer Control, 2015, 22, 515-519.	0.7	0
1007	Induction Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) in Caucasian Patients with Multiple Myeloma: A Single Center Experience. Journal of Blood Disorders & Transfusion, 2015, 06, .	0.1	0
1008	The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. Journal of the National Cancer Institute, 2015, 107, .	3.0	29
1009	Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 840-847.	2.0	5
1010	Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. Expert Opinion on Biological Therapy, 2015, 15, 149-154.	1.4	9

#	ARTICLE	IF	CITATIONS
1011	Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 701-706.	2.0	66
1012	Novel agents have a significant impact on survival of patients with multiple myeloma. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 92-97.	1.0	3
1013	The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 261-271.	1.9	17
1014	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16
1015	Preparation and biological evaluation of ¹⁶⁶ Ho-BPAMD as a potential therapeutic bone-seeking agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2015, 304, 1285-1291.	0.7	8
1016	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. <i>Leukemia and Lymphoma</i> , 2015, 56, 559-567.	0.6	12
1017	Relationship of P-Selectin Glycoprotein Ligand-1 to Prognosis in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 164-170.	0.2	6
1018	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
1019	Current and future immunotherapeutic approaches to multiple myeloma therapy. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 23-31.	0.7	0
1020	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	2.8	48
1021	Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 409-415.e1.	0.2	21
1022	BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 531-535.	0.2	18
1023	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1823-1829.	2.0	30
1024	Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. <i>Bone Marrow Transplantation</i> , 2015, 50, 34-39.	1.3	36
1025	High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1075-1082.	1.3	36
1026	Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 947-953.	1.3	40
1028	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015, 21, 914-921.	15.2	728
1029	Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 536-540.	0.2	28

#	ARTICLE	IF	CITATIONS
1030	A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line. <i>Oncology Letters</i> , 2015, 9, 1719-1724.	0.8	21
1031	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 857-872.	1.4	18
1032	Frontline therapy of multiple myeloma. <i>Blood</i> , 2015, 125, 3076-3084.	0.6	244
1033	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1021-1032.	2.0	27
1034	Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1330-1334.	2.0	10
1035	Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 808-812.	1.3	34
1036	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 770-780.	1.3	9
1037	Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1674-1679.	0.8	23
1038	Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib. <i>Oncolimmunology</i> , 2015, 4, e1038011.	2.1	4
1039	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1513-1518.	1.3	34
1040	Outcome in Multiple Myeloma Patients Eligible for Stem Cell Transplantation: A Single-Center Experience. <i>Oncology</i> , 2015, 89, 196-204.	0.9	5
1041	A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. <i>Leukemia and Lymphoma</i> , 2015, 56, 594-601.	0.6	7
1042	Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 368-376.	0.6	0
1043	Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). <i>Leukemia and Lymphoma</i> , 2015, 56, 608-614.	0.6	14
1044	Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy. <i>Bone Marrow Transplantation</i> , 2015, 50, 663-667.	1.3	11
1045	The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2015, 94, 109-114.	1.1	10
1046	Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2015, 30, 176-182.	0.7	40
1047	Clinical treatment of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2015, 8, 595-611.	1.0	13

#	ARTICLE	IF	CITATIONS
1048	Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor. <i>Transfusion and Apheresis Science</i> , 2015, 53, 23-29.	0.5	22
1049	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 1617-1629.	5.1	289
1050	Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 468-472.	2.0	29
1051	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
1052	Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. <i>Bone Marrow Transplantation</i> , 2015, 50, 209-215.	1.3	108
1053	Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry. <i>Annals of Hematology</i> , 2015, 94, 651-661.	0.8	39
1054	Efficacy of Vinorelbine Plus Granulocyte Colony-Stimulation Factor for CD34+ Hematopoietic Progenitor Cell Mobilization in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 74-80.	2.0	17
1055	Role of stem cell transplant and maintenance therapy in plasma cell disorders. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 504-511.	0.9	2
1056	Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma. <i>Chinese Medical Journal</i> , 2016, 129, 320-325.	0.9	6
1057	First line vs delayed transplantation in myeloma: Certainties and controversies. <i>World Journal of Transplantation</i> , 2016, 6, 321.	0.6	8
1058	The High Effect of Chemomobilization with High-Dose Etoposide + Granulocyte-Colony Stimulating Factor in Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation: A Single Center Experience. <i>Hematology Reports</i> , 2016, 8, 6319.	0.3	11
1059	Potential role of exosome-associated microRNA panels and <i>in vivo</i> environment to predict drug resistance for patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30876-30891.	0.8	89
1060	Multiple myeloma: Looking beyond standards. <i>Asian Journal of Oncology</i> , 2016, 02, 023-028.	0.2	1
1061	Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2752-2762.	0.6	8
1062	Decision tree algorithm for optimized hematopoietic progenitor cell-based predictions in peripheral blood stem cell mobilization. <i>Transfusion</i> , 2016, 56, 2042-2051.	0.8	7
1063	Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases. <i>Molecular and Clinical Oncology</i> , 2016, 4, 107-113.	0.4	3
1064	Effect of melphalan 140 mg/m ² vs 200 mg/m ² on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation—a single center experience. <i>Clinical Transplantation</i> , 2016, 30, 894-900.	0.8	14
1065	Cyclophosphamide plus granulocyte colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2016, 31, 423-428.	0.7	15

#	ARTICLE	IF	CITATIONS
1066	A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant. <i>Journal of Clinical Apheresis</i> , 2016, 31, 559-563.	0.7	6
1067	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016, 51, 1449-1455.	1.3	51
1068	Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 41-49.	0.4	37
1069	Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. <i>Transfusion</i> , 2016, 56, 1394-1401.	0.8	14
1070	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 149-159.	1.1	43
1071	Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2016, 57, 1781-1785.	0.6	5
1072	Cellular and vaccine immunotherapy for multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 521-527.	0.9	16
1073	Role of stem cell transplant and maintenance therapy in plasma cell disorders. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 504-511.	0.9	22
1074	Does the preference of peripheral versus central venous access in peripheral blood stem cell collection/yield change stem cell kinetics in autologous stem cell transplantation?. <i>Transfusion and Apheresis Science</i> , 2016, 54, 76-79.	0.5	3
1075	Melphalan 200 mg/m ² in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. <i>Bone Marrow Transplantation</i> , 2016, 51, 1337-1341.	1.3	30
1076	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2016, 22, 1222-1233.	3.2	96
1077	A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1197-1203.	1.3	28
1078	Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 187-195.	1.1	54
1079	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2159-2164.	2.0	26
1080	Plasma Cell Dyscrasias. <i>Cancer Treatment and Research</i> , 2016, , .	0.2	3
1081	Cost analysis of a randomized stem cell mobilization study in multiple myeloma. <i>Annals of Hematology</i> , 2016, 95, 1653-1659.	0.8	9
1082	Transplantation for Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 227-250.	0.2	2
1083	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 145-167.	0.2	7

#	ARTICLE	IF	CITATIONS
1084	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e340-e351.	2.2	120
1085	New investigational drugs with single-agent activity in multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e451-e451.	2.8	62
1086	Presentation of multiple myeloma mimicking bone metastasis from colon adenocarcinoma: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2016, 4, 31-34.	0.4	4
1089	The effects of allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed multiple myeloma. <i>The Cochrane Library</i> , 0, , .	1.5	0
1090	Multiple myeloma: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 719-734.	2.0	366
1091	Myeloma today: Disease definitions and treatment advances. <i>American Journal of Hematology</i> , 2016, 91, 90-100.	2.0	142
1092	Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 14-20.	0.7	35
1093	Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. <i>Blood Cancer Journal</i> , 2016, 6, e466-e466.	2.8	17
1094	Estimation of human absorbed dose for ¹⁶⁶ Ho-PAM: comparison with ¹⁶⁶ Ho-DOTMP and ¹⁶⁶ Ho-TTHMP. <i>British Journal of Radiology</i> , 2016, 89, 20160153.	1.0	4
1095	A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2165-2171.	2.0	15
1096	Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2603-2610.	1.2	7
1097	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , 2016, 17, e328-e346.	5.1	1,866
1098	Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1681-1691.	2.2	49
1099	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. <i>Haematologica</i> , 2016, 101, 1398-1406.	1.7	28
1100	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	1.1	24
1101	Granulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adults. <i>The Cochrane Library</i> , 0, , .	1.5	0
1102	Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma. <i>International Journal of Hematologic Oncology</i> , 2016, 5, 5-10.	0.7	2
1103	Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy. <i>European Journal of Haematology</i> , 2016, 96, 417-424.	1.1	2

#	ARTICLE	IF	CITATIONS
1104	Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1926-1937.	2.0	16
1105	Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. <i>Cancer</i> , 2016, 122, 618-625.	2.0	21
1106	A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 173, 253-259.	1.2	3
1107	A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. <i>British Journal of Haematology</i> , 2016, 174, 397-409.	1.2	49
1108	Myeloma. , 2016, , 89-100.		0
1109	Improved Prediction of CD34 + Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 763-767.	2.0	6
1110	The role of tandem stem cell transplantation for multiple myeloma patients. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 515-534.	1.4	10
1111	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.2	5
1112	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1009-1016.	2.0	8
1113	Targeting CD138 ^{hi} /CD20 ⁺ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 869-878.	2.0	16
1114	Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years. <i>Transplantation Proceedings</i> , 2016, 48, 177-184.	0.3	17
1115	Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. <i>Blood Cancer Journal</i> , 2016, 6, e378-e378.	2.8	43
1116	Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 999-1001.	1.3	7
1117	Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. <i>Bone Marrow Transplantation</i> , 2016, 51, 479-491.	1.3	77
1118	Multiple Myeloma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2016, 91, 101-119.	1.4	473
1119	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016, 30, 1005-1017.	3.3	204
1120	Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. <i>Bone Marrow Transplantation</i> , 2016, 51, 546-552.	1.3	44
1121	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq1 1 0.784314 rgBT /Over	0.6	7

#	ARTICLE	IF	CITATIONS
1122	Multiple Myeloma and Other Plasma Cell Neoplasms. , 2016, , 1547-1555.e2.		0
1123	A randomized study of melphalan 200â€‰%mg/m2 vs 280â€‰%mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplantation, 2016, 51, 67-71.	1.3	27
1124	Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2016, 51, 2-12.	1.3	16
1125	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biology of Blood and Marrow Transplantation, 2016, 22, 54-60.	2.0	12
1126	Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemoâ€‰mobilization with vinorelbine in multiple myeloma patients. Journal of Clinical Apheresis, 2017, 32, 21-26.	0.7	11
1127	Evaluation of lowâ€‰dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e138-e143.	0.7	2
1128	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 165-172.	0.2	17
1129	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 581-587.	2.0	14
1130	A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?. Current Hematologic Malignancy Reports, 2017, 12, 61-67.	1.2	6
1131	Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 31-40.	0.3	24
1132	Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Investigation, 2017, 35, 195-201.	0.6	11
1133	Impact of induction treatment before autologous stem cell transplantation on longâ€‰term outcome in patients with newly diagnosed multiple myeloma. European Journal of Haematology, 2017, 98, 569-576.	1.1	4
1134	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica, 2017, 102, 922-931.	1.7	34
1135	Associations of Highâ€‰Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. Clinical Pharmacology and Therapeutics, 2017, 102, 511-519.	2.3	28
1136	Toxicities, response and survival: Autologous stem cell transplantation for multiple myeloma over 25 years at a single center. Cancer Treatment and Research Communications, 2017, 11, 1-5.	0.7	0
1137	Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta Haematologica, 2017, 137, 163-172.	0.7	10
1138	Poster Presentations. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 111-640.	0.5	6
1139	How is patient care for multiple myeloma advancing?. Expert Review of Hematology, 2017, 10, 551-561.	1.0	11

#	ARTICLE	IF	CITATIONS
1141	When to recommend a second autograft in patients with relapsed myeloma?. <i>Leukemia and Lymphoma</i> , 2017, 58, 781-787.	0.6	4
1142	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	1.3	5
1143	Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. <i>International Journal of Hematology</i> , 2017, 106, 562-572.	0.7	14
1144	Myeloma; living better and living longer - a look at the advances. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 153-166.	0.6	0
1145	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	2.3	166
1146	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	2.2	19
1147	Posttransplant maintenance therapy in multiple myeloma: the changing landscape. <i>Blood Cancer Journal</i> , 2017, 7, e545-e545.	2.8	40
1148	Transplantation for Myeloma – Now or Later?. <i>New England Journal of Medicine</i> , 2017, 376, 1378-1379.	13.9	5
1149	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	13.9	924
1150	In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1203-1207.	2.0	25
1151	Mechanisms of Resistance in Multiple Myeloma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 251-288.	0.9	20
1152	New agents in HSC mobilization. <i>International Journal of Hematology</i> , 2017, 105, 141-152.	0.7	42
1153	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. <i>Leukemia</i> , 2017, 31, 1727-1734.	3.3	41
1154	Storage Duration of Autologous Stem Cell Preparations Has No Impact on Hematopoietic Recovery after Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 684-690.	2.0	23
1155	Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone. <i>Annals of Hematology</i> , 2017, 96, 461-467.	0.8	7
1156	Myeloma in the Real World: What Is Really Happening?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 133-144.e1.	0.2	34
1157	Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 2071-2078.	0.8	4
1158	Effect of autologous stem-cells transplantation of patients with multiple myeloma on the calorimetric markers of the serum proteome. Correlation with the immunological markers. <i>Thermochimica Acta</i> , 2017, 655, 351-357.	1.2	8

#	ARTICLE	IF	CITATIONS
1159	Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. <i>Oncology</i> , 2017, 93, 295-301.	0.9	4
1160	Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1616-1622.	1.3	44
1161	Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review. <i>European Journal of Haematology</i> , 2017, 99, 479-488.	1.1	8
1162	A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1372-1377.	1.3	13
1163	Impact of lenalidomide-based induction therapy on the mobilization of CD34 ⁺ cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study. <i>Transfusion</i> , 2017, 57, 2366-2372.	0.8	7
1164	Multiple myeloma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17046.	18.1	812
1165	Standardisation of minimal residual disease in multiple myeloma. <i>European Journal of Cancer Care</i> , 2017, 26, e12732.	0.7	9
1166	Możliwość leczenia indukcyjnego chorych na szpiczaka plazmocytozowego kwalifikujących się do chemioterapii wysokodawkowanej wspomaganą autologiczną... transplantacją... komórek krwiotwórczych a aktualne zalecenia Polskiej Grupy Szpiczakowej. <i>Acta Haematologica Polonica</i> , 2017, 48, 104-111.	0.1	0
1168	Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 640.	2.8	19
1169	Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 650-657.	0.2	7
1170	Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1599-1601.	1.3	14
1171	The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2017, 56, 552-557.	0.5	3
1172	High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. <i>BMC Cancer</i> , 2017, 17, 151.	1.1	21
1173	Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. <i>Leukemia</i> , 2017, 31, 1998-2000.	3.3	15
1174	Melphalan hydrochloride for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1127-1136.	0.9	44
1175	Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy. <i>Leukemia and Lymphoma</i> , 2017, 58, 1076-1083.	0.6	18
1176	Upfront use of plerixafor and granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. <i>Leukemia and Lymphoma</i> , 2017, 58, 1123-1129.	0.6	11
1177	Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country. <i>Bone Marrow Transplantation</i> , 2017, 52, 222-227.	1.3	3

#	ARTICLE	IF	CITATIONS
1178	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017, 52, 34-40.	1.3	30
1179	Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 262-268.	2.0	33
1180	Autologous hematopoietic cell transplants for plasma cell myeloma: One, two, or none?. , 0, , 445-457.		0
1181	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. <i>Blood Research</i> , 2017, 52, 293.	0.5	23
1182	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
1183	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. <i>European Journal of Haematology</i> , 2018, 101, 237-244.	1.1	107
1185	Efficacy and Survival Outcome Associated with the Use of Novel Agents and Autologous Stem Cell Transplantation in Cases of Immunoglobulin D Multiple Myeloma in Korea. <i>Acta Haematologica</i> , 2018, 139, 185-192.	0.7	8
1186	Stem cell mobilization kinetics in elderly patients with multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2018, 57, 204-207.	0.5	0
1187	Treatment of Transplant Eligible Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 29-60.	0.2	1
1188	Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 174-179.	0.2	4
1189	FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. <i>Oncologist</i> , 2018, 23, 734-739.	1.9	33
1190	Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. <i>Hematological Oncology</i> , 2018, 36, 436-444.	0.8	13
1191	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1379-1385.	2.0	19
1192	Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1187-1195.	2.0	38
1193	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929.	2.0	10
1194	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 56-58.	1.4	16
1195	DANFIN functions as an inhibitor of transcription factor NF- κ B and potentiates the antitumor effect of bortezomib in multiple myeloma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 2289-2295.	1.0	8
1196	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i> , 2018, 103, 514-521.	1.7	70

#	ARTICLE	IF	CITATIONS
1197	Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 694-699.	2.0	5
1198	Chemo-Mobilization in Myeloma—Diminishing Returns in the Era of Novel Agent Induction?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 203-204.	2.0	1
1199	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	3.4	130
1200	The evolution of stem-cell transplantation in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 123-133.	1.1	31
1201	Cyclophosphamide's addition in relapsed/refractory multiple myeloma patients with biochemical progression during lenalidomide+dexamethasone treatment. <i>European Journal of Haematology</i> , 2018, 101, 160-164.	1.1	3
1202	Hematopoietic stem cell transplantation in geriatric patients in Turkey. <i>Transfusion and Apheresis Science</i> , 2018, 57, 159-162.	0.5	0
1203	Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 701-707.	1.3	16
1204	Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 225-232.	0.6	3
1206	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. <i>Drugs and Aging</i> , 2018, 35, 289-302.	1.3	2
1207	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. , 2018, , 551-571.		0
1208	Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 281-289.	0.5	5
1209	Diagnosis and management of neuropathies associated with plasma cell dyscrasias. <i>Hematological Oncology</i> , 2018, 36, 3-14.	0.8	18
1210	Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2018, 33, 29-37.	0.7	36
1211	NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 175-179.	1.3	7
1212	High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 34-38.	1.3	16
1213	Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2018, 33, 357-370.	0.7	10
1214	Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 276-281.	2.0	16
1215	Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2018, 33, 249-258.	0.7	3

#	ARTICLE	IF	CITATIONS
1216	Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 687-693.	2.0	5
1217	Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 261-267.	0.3	19
1218	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. <i>Blood</i> , 2018, 131, 611-620.	0.6	49
1219	Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 25-31.	0.3	22
1221	Post-Transplantation Management Strategies. , 0, , .		0
1222	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 106.	2.8	16
1224	Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma. <i>Journal of Translational Medicine</i> , 2018, 16, 363.	1.8	12
1225	Toxoplasma Encephalitis following Tandem Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature. <i>Case Reports in Infectious Diseases</i> , 2018, 2018, 1-3.	0.2	5
1226	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 693-702.	0.2	5
1227	The challenges of checkpoint inhibition in the treatment of multiple myeloma. <i>Cellular Immunology</i> , 2018, 334, 87-98.	1.4	15
1228	Pharmacokineticâ€¦Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€¦Dose Melphalan for Autologous Stem Cell Transplant. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 748-758.	1.3	11
1229	Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. <i>Blood</i> , 2018, 132, 1675-1688.	0.6	119
1230	Oral and dental management for people with multiple myeloma: clinical guidance for dental care providers. <i>Dental Update</i> , 2018, 45, 383-399.	0.1	4
1231	Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. <i>Annals of Hematology</i> , 2018, 97, 1869-1877.	0.8	23
1232	Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e315-e325.	0.2	7
1233	Circulating CD3⁺CD4⁺CD161⁺ Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	3
1234	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018, 132, 1114-1124.	0.6	38
1235	Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy. <i>Neoplasia</i> , 2018, 65, 720-729.	0.7	7

#	ARTICLE	IF	CITATIONS
1236	Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect [®] MM Registry. <i>Annals of Hematology</i> , 2018, 97, 2425-2436.	0.8	33
1237	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. <i>Clinical Therapeutics</i> , 2018, 40, 1193-1202.e1.	1.1	10
1238	Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan. <i>International Journal of Hematology</i> , 2018, 108, 423-431.	0.7	3
1239	Plasma Cell Neoplasms. , 2018, , 1381-1418.e1.		4
1240	Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing [®] Sarcoma: A Systematic Review. <i>Sarcoma</i> , 2018, 2018, 1-12.	0.7	15
1241	The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov. <i>Future Oncology</i> , 2018, 14, 1965-1976.	1.1	4
1242	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. <i>Trials</i> , 2018, 19, 169.	0.7	8
1243	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8
1244	Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis. <i>BMC Cancer</i> , 2018, 18, 801.	1.1	3
1245	Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. <i>Hematological Oncology</i> , 2018, 36, 671-678.	0.8	10
1246	Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients. <i>Neoplasma</i> , 2018, 65, 952-957.	0.7	3
1247	Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2018, 93, 1091-1110.	2.0	166
1248	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
1250	Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 253-256.	0.6	0
1251	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 78-85.	3.0	20
1252	Final outcomes of escalated melphalan 280 mg/m ² with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. <i>Bone Marrow Transplantation</i> , 2019, 54, 293-299.	1.3	12
1253	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	0.6	15
1254	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 587-594.	1.3	9

#	ARTICLE	IF	CITATIONS
1255	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	1.3	81
1256	Development of a prognostic model for overall survival in multiple myeloma using the Connect ^{MM} MM Patient Registry. <i>British Journal of Haematology</i> , 2019, 187, 602-614.	1.2	11
1257	The emerging role of exosomes in multiple myeloma. <i>Blood Reviews</i> , 2019, 38, 100595.	2.8	50
1258	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥ 75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	0.6	11
1259	Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. <i>European Journal of Haematology</i> , 2019, 103, 385-392.	1.1	1
1260	High-Dose Chemotherapy Regimens. , 2019, , 37-57.		0
1261	Staging System to Predict the Risk of Relapse in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Frontiers in Oncology</i> , 2019, 9, 633.	1.3	18
1262	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 65.	6.9	7
1263	β -Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. <i>Blood</i> , 2019, 134, 1585-1597.	0.6	209
1264	Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?. <i>Leukemia</i> , 2019, 33, 588-596.	3.3	8
1265	Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. <i>MDM Policy and Practice</i> , 2019, 4, 238146831881425.	0.5	8
1266	The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. <i>Leukemia</i> , 2019, 33, 863-883.	3.3	45
1267	Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: Lesson from a Tertiary Cancer Centre in rural India. <i>Leukemia Research</i> , 2019, 83, 106167.	0.4	5
1268	Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1713-1719.	2.0	7
1269	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2039-2050.	1.3	9
1270	A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1881-1891.	1.3	2
1271	Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e176-e186.	1.8	28
1272	Is there still a role for stem cell transplantation in multiple myeloma?. <i>Cancer</i> , 2019, 125, 2534-2543.	2.0	23

#	ARTICLE	IF	CITATIONS
1273	Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9543-9551.	3.3	266
1274	Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice and Research in Clinical Haematology, 2019, 32, 54-64.	0.7	12
1276	Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2019, 9, 44.	2.8	175
1277	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. Journal of Clinical Oncology, 2019, 37, 589-597.	0.8	184
1278	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematologica, 2019, 141, 111-118.	0.7	4
1279	Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. In Vivo, 2019, 33, 611-619.	0.6	5
1280	GENESIS: Phase III trial evaluating BL-8040+ÂG-CSF to mobilize hematopoietic cells for autologous transplant in myeloma. Future Oncology, 2019, 15, 3555-3563.	1.1	18
1281	Stem-cell transplantation in multiple myeloma: how far have we come?. Therapeutic Advances in Hematology, 2019, 10, 204062071988811.	1.1	18
1282	Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. Biology of Blood and Marrow Transplantation, 2019, 25, 41-46.	2.0	15
1283	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. Blood, 2019, 133, 652-659.	0.6	41
1284	Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid. Bioorganic and Medicinal Chemistry, 2019, 27, 479-482.	1.4	10
1285	Bone marrow transplant and pediatric multiple myeloma. Pediatric Blood and Cancer, 2019, 66, e27528.	0.8	3
1286	Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplantation, 2019, 54, 1029-1037.	1.3	18
1287	Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality. Journal of Clinical Apheresis, 2019, 34, 39-43.	0.7	6
1288	Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Annals of Hematology, 2019, 98, 369-379.	0.8	17
1289	Minimal residual disease and log ₁₀ reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma. Cytometry Part B - Clinical Cytometry, 2019, 96, 195-200.	0.7	11
1290	A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leukemia and Lymphoma, 2019, 60, 1381-1388.	0.6	11
1291	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 239-247.	2.0	27

#	ARTICLE	IF	CITATIONS
1292	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	1.7	25
1293	Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020, 11, 93-99.	0.5	15
1294	Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 199-206.	1.3	12
1295	Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 27-36.	0.6	4
1296	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	1.3	14
1297	Optimized peripheral blood progenitor cell mobilization for autologous hematopoietic cell transplantation in children with high-risk and refractory malignancies. <i>Pediatric Transplantation</i> , 2020, 24, e13602.	0.5	6
1298	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
1299	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	3.4	42
1300	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
1301	Hematopoietic Stem Cell Transplantation. , 2020, , 461-469.e3.		4
1302	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
1303	Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 876-883.	2.0	13
1304	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , 2020, 10, 94.	2.8	178
1305	Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation. <i>Expert Review of Hematology</i> , 2020, 13, 1333-1347.	1.0	1
1306	CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment. <i>Cancer Immunology Research</i> , 2020, 8, 1163-1179.	1.6	17
1307	Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF- κ B signal pathway. <i>Hematology</i> , 2020, 25, 424-432.	0.7	2
1308	Recent Advances in the Treatment of Patients with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3576.	1.7	22
1309	Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 1087.	1.1	42

#	ARTICLE	IF	CITATIONS
1310	Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23416.	0.9	9
1311	Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3101-3111.	0.6	3
1312	The gift that keeps on giving: lenalidomide maintenance after second autologous stem cell transplant in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1780-1783.	0.6	0
1313	Feasibility and efficacy of low-dose pegfilgrastim for CD34 + cell mobilization in lymphoma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 413-419.	0.7	1
1314	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 87.	2.8	13
1315	Syngeneic transplants for multiple myeloma – a single center experience and review of the literature. <i>Leukemia and Lymphoma</i> , 2020, 61, 3519-3522.	0.6	0
1316	Chinese Herbal Medicine Is Helpful for Survival Improvement in Patients With Multiple Myeloma in Taiwan: A Nationwide Retrospective Matched-Cohort Study. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542094328.	0.8	10
1317	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2132-2137.	1.3	8
1318	Incidence and survival of multiple myeloma: a population-based study of 10,524 patients diagnosed 1982–2017. <i>British Journal of Haematology</i> , 2020, 191, 418-425.	1.2	34
1319	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1559-1566.	2.0	6
1320	Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!. <i>Journal of Cellular Physiology</i> , 2020, 235, 9080-9097.	2.0	19
1321	Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1331-1339.	0.8	7
1322	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	0.8	9
1323	Tolerability of high dose chemotherapy and autologous stem cell transplantation in elderly patients with multiple myeloma: A single-center retrospective analysis. <i>Current Research in Translational Medicine</i> , 2020, 68, 139-144.	1.2	4
1324	Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide. <i>Clinical Interventions in Aging</i> , 2020, Volume 15, 619-633.	1.3	10
1325	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e734-e751.	0.2	2
1326	The role of high-dose melphalan with autologous stem cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020, 191, 692-703.	1.2	23
1327	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16

#	ARTICLE	IF	CITATIONS
1328	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	1.3	5
1329	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). Therapeutic Advances in Hematology, 2020, 11, 204062072092104.	1.1	2
1330	Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e752-e768.	0.2	28
1331	Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis. Annals of Hematology, 2020, 99, 1031-1040.	0.8	1
1332	Multiple myeloma: 2020 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 548-567.	2.0	507
1333	Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone. Journal of Clinical Pharmacology, 2020, 60, 1061-1075.	1.0	4
1334	Evaluation of mobilization efficacy with an extended interval following plerixafor administration. Journal of Oncology Pharmacy Practice, 2020, 26, 1590-1597.	0.5	0
1335	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology, 2020, 2020, 1-11.	0.6	46
1336	Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma. European Journal of Haematology, 2020, 105, 30-34.	1.1	2
1337	Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. , 2020, 8, e000286.		11
1338	Management of newly diagnosed transplant ineligible multiple myeloma. Leukemia and Lymphoma, 2020, 61, 2549-2560.	0.6	2
1339	Inferior prognosis in poor mobilizing myeloma patients. Transfusion and Apheresis Science, 2020, 59, 102722.	0.5	4
1340	Total Marrow Irradiation. , 2020, , .		6
1341	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer, 2020, 126, 1837-1855.	2.0	20
1342	The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies – back to the future!. Best Practice and Research in Clinical Haematology, 2020, 33, 101150.	0.7	7
1343	Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 1137-1146.	1.3	7
1344	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 445-452.	0.2	23
1345	Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells. Molecular Cancer Research, 2020, 18, 529-536.	1.5	10

#	ARTICLE	IF	CITATIONS
1346	Autologous haematopoietic stem-cell transplantation versus bortezomib+melphalan+prednisone, with or without bortezomib+lenalidomide+dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e456-e468.	2.2	244
1347	Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. <i>American Journal of Hematology</i> , 2020, 95, 759-765.	2.0	16
1348	Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 407-414.	0.2	8
1349	Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1877-1884.	0.6	4
1350	Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution. <i>BMC Cancer</i> , 2020, 20, 353.	1.1	0
1351	High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 381-387.	0.7	19
1352	Advances & future prospects in newly diagnosed multiple myeloma patients. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.6	1
1353	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApS. <i>Leukemia</i> , 2021, 35, 1134-1144.	3.3	36
1354	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 368-375.	1.3	8
1355	Orthopedic Surgical Treatment and Perioperative Complications in Multiple Myeloma Bone Disease: Analysis of a Series (2009-2018). <i>Annals of Surgical Oncology</i> , 2021, 28, 1158-1166.	0.7	9
1356	Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e384-e397.	0.2	18
1357	Maintenance regimens after a second autologous transplant for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 758-760.	0.6	1
1358	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , 2021, 137, 1527-1537.	0.6	42
1359	Mathematical Models of Cancer and Different Therapies. <i>Series in Bioengineering</i> , 2021, , .	0.3	11
1360	Leveraging minimal residual disease to reassess autologous hematopoietic cell transplantation in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e97.	0.6	0
1361	Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 274-281.	0.5	2
1362	Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072199648.	1.1	1
1363	Transplant Pharmacology and Conditioning Therapy. <i>Organ and Tissue Transplantation</i> , 2021, , 315-346.	0.0	0

#	ARTICLE	IF	CITATIONS
1364	Retrospective Survival Analysis of Multiple Myeloma Patients after Autologous Hematopoietic Stem Cell Transplantation. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 73-79.	0.1	2
1365	DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 504.	1.7	14
1366	Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study. <i>Leukemia Research Reports</i> , 2021, 15, 100252.	0.2	3
1367	Role of Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 863.	1.7	17
1368	Chemotherapy-based regimens in multiple myeloma in 2020. <i>Panminerva Medica</i> , 2021, 63, 7-12.	0.2	10
1369	Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience. <i>Internal Medicine Journal</i> , 2021, 51, 280-283.	0.5	3
1370	Efficacy of reduced dose melphalan conditioning for multiple myeloma patients undergoing autologous stem cell transplantation: in the era of combined induction with novel agents. <i>Journal of Health Sciences and Medicine</i> , 2021, 4, 203-208.	0.0	0
1371	Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?. <i>Frontiers in Immunology</i> , 2021, 12, 651288.	2.2	8
1372	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 154-161.e3.	0.2	11
1373	How to Treat High-Risk Myeloma at Diagnosis and Relapse. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 291-309.	1.8	27
1374	Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. <i>British Journal of Haematology</i> , 2021, 193, 245-268.	1.2	24
1375	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 243.e1-243.e6.	0.6	1
1376	Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation. <i>Cancers</i> , 2021, 13, 1702.	1.7	9
1377	Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. <i>Drugs</i> , 2021, 81, 825-840.	4.9	6
1378	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018.	1.3	2
1379	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. <i>Pathology</i> , 2021, 53, 385-399.	0.3	12
1380	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. <i>Vaccines</i> , 2021, 9, 509.	2.1	14
1381	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , 2021, 56, 2533-2543.	1.3	7

#	ARTICLE	IF	CITATIONS
1382	Current and Novel Alkylators in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2465.	1.7	12
1383	A novel phosphoramidate compound, DCZ0805, shows potent anti-myeloma activity via the NF- κ B pathway. <i>Cancer Cell International</i> , 2021, 21, 285.	1.8	2
1384	Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience. <i>Journal of Clinical Apheresis</i> , 2021, 36, 634-644.	0.7	3
1385	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 275-282.	1.1	8
1386	A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. <i>Nano Letters</i> , 2021, 21, 5158-5166.	4.5	14
1387	The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 11789.	1.6	2
1388	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2664-2671.	1.3	9
1389	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e510-e520.	0.2	12
1390	Study of Peripheral Mononuclear Cells and CD34 Levels as a Predictive Marker for Initiating Apheresis in Autologous Stem Cell Transplant. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2021, 15, 170-177.	0.3	0
1391	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. <i>International Journal of Cancer</i> , 2021, 149, 1980-1996.	2.3	25
1392	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18 F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
1393	Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. <i>Drugs - Real World Outcomes</i> , 2022, 9, 63-78.	0.7	5
1394	Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. <i>Cancers</i> , 2021, 13, 4332.	1.7	6
1395	Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. <i>Supportive Care in Cancer</i> , 2022, 30, 585-591.	1.0	4
1396	The evolving role and utility of off-label drug use in multiple myeloma. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	0
1397	Does myeloma genetic have an effect on stem cell mobilization?. <i>Transfusion and Apheresis Science</i> , 2021, , 103249.	0.5	0
1398	The role of autologous stem-cell transplantation in multiple myeloma in 2021. <i>Current Opinion in Oncology</i> , 2021, 33, 642-647.	1.1	5
1399	Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 2124-2138.	1.7	3

#	ARTICLE	IF	CITATIONS
1400	Addition of plerixafor for mobilization of stem cells with bortezomib is feasible in dialysis-dependent multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2021, , 103279.	0.5	1
1401	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 770.e1-770.e7.	0.6	6
1402	Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 876.e1-876.e11.	0.6	8
1403	Estimation of radiation absorbed dose in man from ¹⁶⁶ Ho-EDTMP based on biodistribution data in Wistar rats. <i>Radiation Physics and Chemistry</i> , 2021, 187, 109560.	1.4	2
1404	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation—A Blood or Marrow Transplant Survivor Study Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 840.e1-840.e7.	0.6	2
1405	Bone remodeling: analysis, discussion, and perspectives. , 2021, , 207-218.		0
1406	Investigation of characterization and cytotoxic effect of PEGylated nanoliposomal containing Melphalan on ovarian cancer: an <i>in vitro</i> study. <i>Journal of Experimental Nanoscience</i> , 2021, 16, 102-116.	1.3	4
1407	Comparison of single and double autologous stem cell transplantation in multiple myeloma patients. <i>Open Medicine (Poland)</i> , 2021, 16, 192-197.	0.6	2
1408	Myeloma. , 0, , 681-702.		2
1409	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 1262-1282.		1
1410	High-dose Preparatory Regimens. , 0, , 316-332.		3
1412	The Principles and Overview of Autologous Hematopoietic Stem Cell Transplantation. <i>Cancer Treatment and Research</i> , 2009, 144, 23-45.	0.2	6
1413	Inhibition of TGF- β 2 Signaling in Multiple Myeloma and Its Bone Marrow Microenvironment. , 2008, , 219-227.		1
1415	High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Recent Results in Cancer Research</i> , 2011, 183, 207-238.	1.8	2
1416	Firstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients. <i>Recent Results in Cancer Research</i> , 2011, 183, 189-206.	1.8	20
1417	Myeloma and Secondary Involvement of the Kidney in Dysproteinemias. , 2008, , 461-468.		1
1418	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.	2.0	8
1419	Management of mobilization failure in 2017. <i>Transfusion and Apheresis Science</i> , 2017, 56, 836-844.	0.5	12

#	ARTICLE	IF	CITATIONS
1420	DNA-binding agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 171-209.	0.5	5
1421	DNA-binding agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 163-203.	0.5	5
1422	Plasma cell dyscrasias and leukemias. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 343-389.	0.5	1
1423	Long-term Outcomes in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2018, 2, e45.	1.2	38
1424	The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. <i>Singapore Medical Journal</i> , 2017, 58, 55-71.	0.3	6
1425	Immunotherapy of multiple myeloma. <i>Journal of Clinical Investigation</i> , 2020, 130, 1565-1575.	3.9	103
1426	Bone marrow transplantation generates T cell-dependent control of myeloma in mice. <i>Journal of Clinical Investigation</i> , 2018, 129, 106-121.	3.9	49
1427	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 255-261.	0.9	16
1428	A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma. <i>Blood</i> , 2010, 116, 2387-2387.	0.6	1
1429	Recent advances in understanding multiple myeloma. <i>F1000Research</i> , 2016, 5, 2053.	0.8	13
1430	Lenalidomide Treatment for Multiple Myeloma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e64354.	1.1	40
1431	BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. <i>Oncotarget</i> , 2017, 8, 56858-56867.	0.8	7
1432	Stem cell harvesting protocol research in autologous transplantation setting: Large volume vs. conventional cytopheresis. <i>Vojnosanitetski Pregled</i> , 2008, 65, 545-551.	0.1	15
1434	Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The National Cancer Institute of Canada Clinical Trials Group MY.11 Trial. <i>Current Oncology</i> , 2007, 14, 61-65.	0.9	7
1435	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	0.8	4
1436	Predictive Value of Post-Transplant Bone Marrow Plasma Cell Percent in Multiple Myeloma Patients Undergone Autologous Transplantation. <i>Korean Journal of Internal Medicine</i> , 2011, 26, 76.	0.7	3
1437	Recent advances in multiple myeloma: a Korean perspective. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 820-834.	0.7	22
1438	Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 722-730.	0.7	7

#	ARTICLE	IF	CITATIONS
1439	Multiple myeloma: Experience of an institute in limited resource setting. Indian Journal of Cancer, 2017, 54, 340.	0.2	12
1440	High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome. Indian Journal of Medical Research, 2019, 149, 730.	0.4	23
1441	Transactivating Target Gene Expression by Recombinant SALL4B: A Pluripotent Stem Cell Marker. Journal of Stem Cell Research & Therapy, 2014, 04, .	0.3	1
1442	Frontline therapy for newly diagnosed patients with multiple myeloma. Blood Research, 2020, 55, S37-S42.	0.5	12
1443	Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?. World Journal of Transplantation, 2017, 7, 250-259.	0.6	11
1444	Treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis. Folia Histochemica Et Cytobiologica, 2011, 49, 248-254.	0.6	2
1445	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
1446	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 599-634.	2.3	33
1447	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	2.3	138
1448	Clinical Study of Thalidomide Combined with Dexamethasone for the Treatment of Elderly Patients with Newly Diagnosed Multiple Myeloma. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4777-4781.	0.5	3
1449	C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Cureus, 2018, 10, e2945.	0.2	5
1450	Physical therapy for multiple myeloma patients with severely hindered daily living activities due to bone lesions: a report of two cases. Journal of Physical Therapy Science, 2021, 33, 795-800.	0.2	0
1451	Clarifying the molecular mechanism of tomentosinâ€induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. International Journal of Molecular Medicine, 2021, 48, .	1.8	2
1452	Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. Cytotherapy, 2022, 24, 49-58.	0.3	5
1453	The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Advances, 2021, 5, 4327-4337.	2.5	9
1454	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and Cellular Therapy, 2022, 28, 75.e1-75.e7.	0.6	5
1455	Autologous and Allogeneic Transplantation for Multiple Myeloma. , 2004, , 85-97.		1
1456	Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma. , 2004, , 159-182.		0

#	ARTICLE	IF	CITATIONS
1457	Allogeneic Transplantation in Multiple Myeloma. , 2004, , 183-203.		0
1458	Treatment of Multiple Myeloma. , 2004, , 137-157.		0
1459	Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias. , 2004, , 281-302.		0
1460	Autologous stem cell transplantation. , 2004, , 250-259.		0
1462	Multiples Myelom. Pharma-Kritik (discontinued), 2005, 26, .	0.0	0
1463	Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2005, 106, 2893-2893.	0.6	1
1464	Multiples Myelom. , 2006, , 3165-3205.		0
1465	Multiples Myelom und verwandte Plasmazellerkrankungen. , 2007, , 1-12.		0
1466	Plasmazellerkrankungen. , 2007, , 493-510.		0
1467	Prognostic Factors and Classification in Multiple Myeloma. Translational Medicine Series, 2007, , 115-140.	0.0	0
1469	Chemotherapy for Tumors of the Spine. , 2008, , 317-326.		0
1470	Multiple Myeloma and Related Disorders. , 2008, , 2323-2351.		1
1471	Allogeneic Transplantation for Multiple Myeloma. , 2008, , 125-142.		0
1473	Role of Autologous Stem Cell Transplantation in Multiple Myeloma. , 2008, , 79-90.		0
1474	Stem Cell Transplantation in Multiple. , 2008, , 149-166.		0
1475	Evolving Indications for Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Other Plasma Cell Disorders. Cancer Treatment and Research, 2009, 144, 317-355.	0.2	0
1477	Dysproteinemias and Amyloidosis. , 2009, , 232-241.		4
1479	The Role of Allogeneic Bone Marrow Transplant in Cancer Treatment. , 2010, , 229-239.		0

#	ARTICLE	IF	CITATIONS
1480	The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 0, 31, .	0.7	0
1481	Single Versus Tandem Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma. , 2010, , 143-157.		0
1482	Allogeneic Transplantation for the Treatment of Multiple Myeloma. , 2010, , 261-279.		0
1484	Plasma Cell Tumors. , 2010, , 1394-1399.		0
1486	High-Dose Therapy in Amyloidosis. , 2010, , 165-177.		0
1487	Transplante de células-tronco hematopoiéticas em gamopatias monoclonais. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 0, 32, 115-124.	0.7	0
1489	Prognostic factors and risk adaptation. , 2010, , 922-938.		0
1490	The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma. , 2011, , 69-77.		0
1492	Current Status of BoneMarrow Transplantation for Treatment of Cancer. , 2011, , 407-435.		0
1493	Multiple Myeloma and Plasmacytoma. <i>Medical Radiology</i> , 2011, , 811-832.	0.0	0
1494	Hämatologische und onkologische Erkrankungen. , 2011, , 607-718.		0
1497	Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. <i>Swiss Medical Weekly</i> , 2011, 141, w13203.	0.8	8
1498	Stem Cell Mobilization in Multiple Myeloma. , 0, , .		0
1499	Multiple Myeloma and Other Plasma Cell Neoplasms. , 2012, , 1573-1581.		0
1501	Alternative Sources of Hematopoietic Stem Cells and Their Clinical Applications. , 2013, , 1289-1306.		0
1502	Harnessing Allogeneic Immunity for Anti-myeloma Response. , 2013, , 111-129.		0
1503	Multiple Myeloma Surveillance Counterpoint: Japan. , 2013, , 501-502.		0
1504	A detailed approach on multiple myeloma and its treatment. <i>International Journal of Basic and Clinical Pharmacology</i> , 2013, 2, 671.	0.0	0

#	ARTICLE	IF	CITATIONS
1505	Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Medicine Research</i> , 2013, 5, 174-84.	0.6	14
1506	Proteasome Inhibition and Hematopoietic Stem Cell Transplantation in Multiple Myeloma. , 0, , .		0
1507	Autologous Stem Cell Transplantation in the Management of Multiple Myeloma. , 2014, , 101-123.		0
1509	Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies. , 2014, , 149-182.		0
1510	Multiple Myeloma and Related Disorders. , 2014, , 1991-2017.e7.		1
1512	A Case of Occipito-Thoracic Fusion for Skull Base and Cervical Multiple Myeloma. <i>Journal of Spine</i> , 2015, 04, .	0.2	0
1513	Treatment of transplant-eligible patients. , 2015, , 29-40.		0
1514	Successful collection of stem cells in one day in the process of autologous stem cell transplantation. <i>IFMBE Proceedings</i> , 2017, , 796-801.	0.2	0
1515	Stem Cell Transplantation for Multiple Myeloma. <i>Pancreatic Islet Biology</i> , 2017, , 73-86.	0.1	0
1517	Role of Hematopoietic Cell Transplantation for Myeloma. , 2018, , 573-583.		0
1518	Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of New Drugs. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2018, 11, 187-191.	0.1	0
1519	Uso del plerixafor en pacientes pobres movilizadores para trasplante autÃ³logo.. <i>Revista Colombiana De HematologÃ­a Y OncologÃ­a</i> , 2018, 5, 23-27.	0.0	0
1520	Factors Associated with Efficient Harvesting and Engraftment of Auto-Transplants in Multiple Myeloma Patients. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 32-36.	0.1	1
1521	Minimal Residual Disease Assessment in Myeloma. , 2019, , 231-245.		0
1522	Hematopoietic Cell Transplantation in Patients With Multiple Myeloma. , 2019, , 245-253.		1
1523	Predictive Factors for Early Relapse in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplant. , 2019, 23, .		7
1524	Small Centers with Big Ventures: Autologous Stem Cell Transplantation Survival Data. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 987-990.	0.5	0
1525	Autologiczna transplantacja komÃ³rek krwiotwÃ³rczych u chorych na szpiczaka plazmocytoowego w dobie nowych terapii. <i>Acta Haematologica Polonica</i> , 2019, 50, 130-134.	0.1	0

#	ARTICLE	IF	CITATIONS
1526	CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turkish Journal of Medical Sciences, 2020, 50, 1851-1856.	0.4	7
1527	Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, 2020, Online ahead of print, 0-0.	1.7	16
1528	Is absence of CD56 a predictive factor for peripheral blood stem cell mobilization failure in patients with multiple myeloma?. Journal of Clinical Apheresis, 2021, 36, 332-339.	0.7	2
1529	Total Marrow Irradiation in Multiple Myeloma. , 2020, , 145-154.		1
1530	HÄmatologische und onkologische Erkrankungen. , 2020, , 329-335.		0
1531	The Outcome of Autologous Stem Cell Transplantation in Adolescent and Young Adult Patients with Multiple Myeloma. Eurasian Journal of Medicine and Oncology, 0, , .	1.0	0
1532	Transplant Pharmacology and Conditioning Therapy. Organ and Tissue Transplantation, 2020, , 1-32.	0.0	0
1533	The Efficacy and Safety of Plerixafor in Hematopoietic Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma, Multiple Myeloma, and Hodgkin Lymphoma Who Failed Mobilization with Granulocyte-Colony-Stimulating Factor Alone: A Single-Center Experience. Indian Journal of Medical and Paediatric Oncology. 2020. 41. 530-534.	0.1	0
1534	High-dose chemotherapy following autologous hematopoietic stem cell transplantation for multiple myeloma in the real world setting. Single-center experience. Journal of Modern Oncology, 2020, 22, 126-132.	0.1	0
1537	Monoklonale Gammopathien. , 2005, , 1148-1162.		0
1538	Hochdosistherapien. , 0, , 143-194.		0
1539	Multiples Myelom. , 0, , 421-455.		0
1542	Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Therapeutics and Clinical Risk Management, 2007, 3, 543-52.	0.9	9
1543	Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clinical Biochemist Reviews, 2009, 30, 93-103.	3.3	18
1544	Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. American Journal of Blood Research, 2012, 2, 9-17.	0.6	6
1545	Bortezomib: the evidence of its clinical impact in multiple myeloma. Core Evidence, 2006, 1, 265-77.	4.7	1
1546	Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma. Journal of Research in Medical Sciences, 2012, 17, 8-14.	0.4	36
1547	Economic evaluation of plerixafor for stem cell mobilization. American Journal of Managed Care, 2012, 18, 33-41.	0.8	25

#	ARTICLE	IF	CITATIONS
1549	Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 12202-10.	1.3	1
1551	The Paraprotein - an Enduring Biomarker. <i>Clinical Biochemist Reviews</i> , 2019, 40, 5-22.	3.3	16
1552	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 559-568.	0.3	8
1553	VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2020, 14, 248-256.	0.3	1
1556	Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1691-1702.	0.5	1
1557	Multiples Myelom. , 2016, , 1-17.		0
1558	VAD Chemotherapy Versus Bortezomib Containing Regimens As Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2020, 14, 248-256.	0.3	1
1559	Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 101-110.	3.0	0
1560	Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study. <i>Leukemia Research</i> , 2022, 115, 106793.	0.4	4
1561	Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. <i>Cells</i> , 2022, 11, 606.	1.8	8
1562	Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. <i>Hematology</i> , 2022, 27, 239-248.	0.7	0
1563	Hematopoietic Stem Cell Transplantation in Nepal: International Partnership, Implementation Steps, and Clinical Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 268-275.	0.6	8
1564	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	0.6	1
1565	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study. <i>Cancer Reports</i> , 2022, 5, e1614.	0.6	1
1566	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 284-293.	0.6	11
1567	Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e405-e413.	0.2	2
1568	Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. <i>Bone Marrow Transplantation</i> , 2022, 57, 959-965.	1.3	7
1569	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. , 0, , 155-183.		0

#	ARTICLE	IF	CITATIONS
1571	The Molecular Biology of Multiple Myeloma. , 0, , 115-124.		0
1572	Evolution or revolution in multiple myeloma therapy and the role of the UK. British Journal of Haematology, 2020, 191, 542-551.	1.2	3
1574	Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study. , 2022, 39, 300-308.		1
1575	Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. Cancers, 2022, 14, 2228.	1.7	3
1576	Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation. Cancer and Metastasis Reviews, 2022, 41, 367-382.	2.7	6
1577	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 2022, 139, 2747-2757.	0.6	16
1578	Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation. Transplantation and Cellular Therapy, 2022, 28, 367.e1-367.e9.	0.6	4
1579	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2022, 97, 1086-1107.	2.0	208
1580	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Frontiers in Oncology, 2022, 12, .	1.3	9
1581	Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case-control study. European Journal of Haematology, 2022, 109, 250-256.	1.1	3
1582	The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice. Frontiers in Oncology, 2022, 12, .	1.3	3
1583	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia and Lymphoma, 0, , 1-10.	0.6	1
1584	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology, 2022, 97, 1170-1177.	2.0	3
1585	Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. Frontiers in Oncology, 0, 12, .	1.3	2
1586	The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas". Cancers, 2022, 14, 3271.	1.7	5
1587	Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan. Japanese Journal of Clinical Oncology, 0, , .	0.6	1
1588	Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. Pharmaceutics, 2022, 14, 1784.	2.0	2
1589	Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant (HSCT) in Multiple Myeloma Patients: 5-year Experience from a Single Centre in North India. South Asian Journal of Cancer, 0, , .	0.2	1

#	ARTICLE	IF	CITATIONS
1590	Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	1
1591	High-Dose Melphalan Is the Tom Brady of the Myeloma World. , 2022, 19, .		0
1592	Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia. Current Oncology, 2022, 29, 6236-6244.	0.9	2
1593	Updates on Multiple Myeloma: What's New in Risk Stratification, Treatment, and Prognosis. , 0, , .		0
1595	Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis. Frontiers in Pharmacology, 0, 13, .	1.6	8

1596 Risk and response adapted therapy following autologous stem cell transplant in patients with newly

#	ARTICLE	IF	CITATIONS
1609	Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices. PLoS ONE, 2023, 18, e0283241.	1.1	0
1610	Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers. The European Research Journal, 0, , 1-12.	0.1	0
1613	Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy. Advances in Experimental Medicine and Biology, 2023, , .	0.8	0
1615	Hematopoietic Cell Transplantation in Multiple Myeloma. , 2024, , 297-307.		0
1616	Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies. , 2024, , 125-143.		0